

# Evidence-based guidelines for treatment of uterine body neoplasm in Japan: Japan Society of Gynecologic Oncology (JSGO) 2009 edition

## Chapter 1: Overview of guidelines

## Chapter 2: Initial Treatment

### CQ01

- 1) Sato R, Jobo T, Kuramoto H. Parametrial spread is a prognostic factor in endometrial carcinoma. *Eur J Gynaecol Oncol* 2003; 24: 241-5 (Level III)
- 2) Yura Y, Tauchi K, Koshiyama M, Konishi I, Yura S, Mori T, et al. Parametrial involvement in endometrial carcinomas: Its incidence and correlation with other histological parameters. *Gynecol Oncol* 1996; 63: 114-9 (Level III)
- 3) Rutledge F. The role of radical hysterectomy in adenocarcinoma of the endometrium. *Gynecol Oncol* 1974; 2: 331-47 (Level III)
- 4) Carey MS, O'Connell GJ, Johanson CR, Goodyear MD, Murphy KJ, Daya DM, et al. Good outcome associated with a standardized treatment protocol using selective postoperative radiation in patients with clinical stage I adenocarcinoma of the endometrium. *Gynecol Oncol* 1995; 57: 138-44 (Level III)
- 5) Belinson JL, Lee KR, Badger GJ, Pretorius RG, Jarrell MA. Clinical stage I adenocarcinoma of the endometrium—analysis of recurrences and the potential benefit of staging lymphadenectomy. *Gynecol Oncol* 1992; 44: 17-23 (Level III)
- 6) Paterson E, Spratt D, Tomkiewicz Z, Lewis C, Rathbun P. Management of stage I carcinoma of the uterus. *Obstet Gynecol* 1982; 59: 755-8 (Level III)
- 7) Sant Cassia LJ, Weppelmann B, Shingleton H, Soong SJ, Hatch K, Salter MM. Management of early endometrial carcinoma. *Gynecol Oncol* 1989; 35: 362-6 (Level III)
- 8) Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A Gynecologic Oncology Group study. *Gynecol Oncol* 1991; 40: 55-65 (Level II)
- 9) 日本産科婦人科学会子宮癌登録委員会: 全国子宮体癌調査成績. 第4報. 1989-1990年度症例. 日本産科婦人科学会, 東京, 1999; 32 (Level IV)

### CQ02

- 1) Leminen A, Forss M, Lehtovirta P. Endometrial adenocarcinoma with clinical evidence of cervical involvement: Accuracy of diagnostic procedures, clinical course, and prognostic factors. *Acta Obstet Gynecol Scand* 1995; 74: 61-6 (Level III)

- 2) Boente MP, Yordan EL Jr, McIntosh DG, Grendys EC Jr, Orandi YA, Davies S, et al. Prognostic factors and long-term survival in endometrial adenocarcinoma with cervical involvement. *Gynecol Oncol* 1993; 51: 316-22 (Level III)
- 3) Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A Gynecologic Oncology Group study. *Gynecol Oncol* 1991; 40: 55-65 (Level II)
- 4) Mannel RS, Berman ML, Walker JL, Manetta A, DiSaia PJ. Management of endometrial cancer with suspected cervical involvement. *Obstet Gynecol* 1990; 75: 1016-22 (Level III)
- 5) Sato R, Jobo T, Kuramoto H. Parametrial spread is a prognostic factor in endometrial carcinoma. *Eur J Gynaecol Oncol* 2003; 24: 241-5 (Level III)
- 6) Sartori E, Gadducci A, Landoni F, Lissoni A, Maggino T, Zola P, et al. Clinical behavior of 203 stage II endometrial cancer cases: The impact of primary surgical approach and of adjuvant radiation therapy. *Int J Gynecol Cancer* 2001; 11: 430-7 (Level III)
- 7) Mariani A, Webb MJ, Keeney GL, Calori G, Podratz KC. Role of wide/radical hysterectomy and pelvic lymph node dissection in endometrial cancer with cervical involvement. *Gynecol Oncol* 2001; 83: 72-80 (Level III)
- 8) Cornelison TL, Trimble EL, Kosary CL. SEER data, corpus uteri cancer: Treatment trends versus survival for FIGO stage II, 1988-1994. *Gynecol Oncol* 1999; 74: 350-5 (Level III)
- 9) Eltabbakh GH, Moore AD. Survival of women with surgical stage II endometrial cancer. *Gynecol Oncol* 1999; 74: 80-5 (Level III)
- 10) Homesley HD, Boronow RC, Lewis JL Jr. Stage II endometrial adenocarcinoma. Memorial Hospital for Cancer, 1949-1965. *Obstet Gynecol* 1977; 49: 604-8 (Level III)
- 11) Creasman WT, DeGeest K, DiSaia PJ, Zaino RJ. Significance of true surgical pathologic staging: A Gynecologic Oncology Group study. *Am J Obstet Gynecol* 1999; 181: 31-4 (Level III)
- 12) Yura Y, Tauchi K, Koshiyama M, Konishi I, Yura S, Mori T, et al. Parametrial involvement in endometrial carcinomas: Its incidence and correlation with other histological parameters. *Gynecol Oncol* 1996; 63: 114-9 (Level III)
- 13) Tamussino KF, Reich O, Gücer F, Moser F, Zivkovic F, Lang PF, et al. Parametrial spread in patients with endometrial carcinoma undergoing radical hysterectomy. *Int J Gynecol Cancer* 2000; 10: 313-7 (Level III)

### CQ03

- 1) Kilgore LC, Partridge EE, Alvarez RD, Austin JM, Shingleton HM, Noojin F 3rd, et al. Adenocarcinoma of the endometrium: Survival comparisons of patients with and without pelvic node sampling. *Gynecol Oncol* 1995; 56: 29-33 (Level III)
- 2) Fanning J. Long-term survival of intermediate risk endometrial cancer (Stage IG3, IC, II) treated with full lymphadenectomy and brachytherapy without teletherapy. *Gynecol Oncol* 2001; 82: 371-4 (Level III)
- 3) Takeshima N, Hirai Y, Tanaka N, Yamawaki T, Yamauchi K, Hasumi K. Pelvic lymph node metastasis in endometrial cancer with no myometrial invasion. *Obstet Gynecol* 1996; 88: 280-2 (Level III)
- 4) Larson DM, Broste SK, Krawisz BR. Surgery without radiotherapy for primary treatment of endometrial cancer. *Obstet Gynecol* 1998; 91: 355-9 (Level III)
- 5) Cragun JM, Havrilesky LJ, Calingaert B, Synan I, Secord AA, Soper JT, et al. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. *J Clin Oncol* 2005; 23: 3668-75 (Level III)
- 6) Trimble EL, Kosary C, Park RC. Lymph node sampling and survival in endometrial cancer. *Gynecol Oncol* 1998; 71: 340-3 (Level III)
- 7) Candiani GB, Belloni C, Maggi R, Colombo G, Frigoli A, Carinelli SG. Evaluation of different surgical approaches in the treatment of endometrial cancer at FIGO stage I. *Gynecol Oncol* 1990; 37: 6-8 (Level III)
- 8) Bar-Am A, Ron IG, Kuperminc M, Gal I, Jaffa A, Kovner F, et al. The role of routine pelvic lymph node sampling in patients with stage I endometrial carcinoma: Second thoughts. *Acta Obstet Gynecol Scand* 1998; 77: 347-50 (Level III)
- 9) Sartori E, Gadducci A, Landoni F, Lissoni A, Maggino T, Zola P, et al. Clinical behavior of 203 stage II endometrial cancer cases: The impact of primary surgical approach and of adjuvant radiation therapy. *Int J Gynecol Cancer* 2001; 11: 430-7 (Level III)
- 10) ASTEC study group, Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC-ASTEC trial): A randomised study. *Lancet* 2009; 373: 125-36 (Level II)
- 11) Benedetti Panici P, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G, et al. Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: Randomized clinical trial. *J Natl Cancer Inst* 2008; 100: 1707-16 (Level II)
- 12) Ayhan A, Tuncer R, Tuncer ZS, Yüce K, Küçükali T. Correlation between clinical and histopathologic risk factors and lymph node metastases in early

endometrial cancer (a multivariate analysis of 183 cases). *Int J Gynecol Cancer* 1994; 4: 306-9 (Level III)

13) Yenen MC, Dilek S, Dede M, Goktolga U, Deveci MS, Aydogu T. Pelvic-paraaortic lymphadenectomy in clinical stage I endometrial adenocarcinoma: A multicenter study. *Eur J Gynaecol Oncol* 2003; 24: 327-9 (Level III)

14) Lo KW, Cheung TH, Yu MY, Yim SF, Chung TK. The value of pelvic and para-aortic lymphadenectomy in endometrial cancer to avoid unnecessary radiotherapy. *Int J Gynecol Cancer* 2003; 13: 863-9 (Level III)

15) Onda T, Yoshikawa H, Mizutani K, Mishima M, Yokota H, Nagano H, et al. Treatment of node-positive endometrial cancer with complete node dissection, chemotherapy and radiation therapy. *Br J Cancer* 1997; 75: 1836-41 (Level III)

16) Chan JK, Cheung MK, Huh WK, Osann K, Husain A, Teng NN, et al. Therapeutic role of lymph node resection in endometrioid corpus cancer: A study of 12,333 patients. *Cancer* 2006; 107: 1823-30 (Level III)

17) Mariani A, Webb MJ, Keeney GL, Haddock MG, Calori G, Podratz KC. Low-risk corpus cancer: Is lymphadenectomy or radiotherapy necessary? *Am J Obstet Gynecol* 2000; 182: 1506-19 (Level III)

18) Kim YB, Niloff JM. Endometrial carcinoma: Analysis of recurrence in patients treated with a strategy minimizing lymph node sampling and radiation therapy. *Obstet Gynecol* 1993; 82: 175-80 (Level III)

19) Leijon T, Rosenberg P, Boeryd B. Total abdominal hysterectomy and bilateral salpingo-oophorectomy. A sufficient treatment for patients with low risk endometrial carcinoma. *Int J Gynecol Cancer* 1997; 7: 376-80 (Level III)

20) Todo Y, Sakuragi N, Nishida R, Yamada T, Ebina Y, Yamamoto R, et al. Combined use of magnetic resonance imaging, CA125 assay, histologic type, and histologic grade in the prediction of lymph node metastasis in endometrial carcinoma. *Am J Obstet Gynecol* 2003; 188: 1265-72 (Level III)

21) Watanabe M, Aoki Y, Kase H, Fujita K, Tanaka K. Low risk endometrial cancer: A study of pelvic lymph node metastasis. *Int J Gynecol Cancer* 2003; 13: 38-41 (Level III)

#### **CQ04**

1) Yokoyama Y, Maruyama H, Sato S, Saito Y. Indispensability of pelvic and paraaortic lymphadenectomy in endometrial cancers. *Gynecol Oncol* 1997; 64: 411-7 (Level III)

2) Nishiya M, Sakuragi N, Hareyama H, Ebina Y, Furuya M, Oikawa M, et al.

Cox multivariate regression models for estimating prognosis of patients with endometrioid adenocarcinoma of the uterine corpus who underwent thorough surgical staging. *Int J Cancer* 1998; 79: 521-5 (Level III)

3) Fanning J. Long-term survival of intermediate risk endometrial cancer (stage IG3, IC, II) treated with full lymphadenectomy and brachytherapy without teletherapy. *Gynecol Oncol* 2001; 82: 371-4 (Level III)

4) Larson DM, Broste SK, Krawisz BR. Surgery without radiotherapy for primary treatment of endometrial cancer. *Obstet Gynecol* 1998; 91: 355-9 (Level III)

5) Mariani A, Webb MJ, Galli L, Podratz KC. Potential therapeutic role of para-aortic lymphadenectomy in node-positive endometrial cancer. *Gynecol Oncol* 2000; 76: 348-56 (Level III)

6) Onda T, Yoshikawa H, Mizutani K, Mishima M, Yokota H, Nagano H, et al. Treatment of node-positive endometrial cancer with complete node dissection, chemotherapy and radiation therapy. *Br J Cancer* 1997; 75: 1836-41 (Level III)

7) Ayhan A, Tuncer R, Tuncer ZS, Yüce K, Küçükali T. Correlation between clinical and histopathologic risk factors and lymph node metastases in early endometrial cancer (a multivariate analysis of 183 cases). *Int J Gynecol Cancer* 1994; 4: 306-9 (Level III)

8) Faught W, Krepart GV, Lotocki R, Heywood M. Should selective paraaortic lymphadenectomy be part of surgical staging for endometrial cancer ? *Gynecol Oncol* 1994; 55: 51-5 (Level III)

9) Cragun JM, Havrilesky LJ, Calingaert B, Synan I, Secord AA, Soper JT, et al. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. *J Clin Oncol* 2005; 23: 3668-75 (Level III)

10) Lo KW, Cheung TH, Yu MY, Yim SF, Chung TK. The value of pelvic and para-aortic lymphadenectomy in endometrial cancer to avoid unnecessary radiotherapy. *Int J Gynecol Cancer* 2003; 13: 863-9 (Level III)

11) Jobo T, Sato R, Arai T, Tamura T, Watanabe J, Kuramoto H. Lymph node pathway in the spread of endometrial carcinoma. *Eur J Gynaecol Oncol* 2005; 26: 167-9 (Level III)

12) Hirahatake K, Hareyama H, Sakuragi N, Nishiya M, Makinoda S, Fujimoto S. A clinical and pathologic study on para-aortic lymph node metastasis in endometrial carcinoma. *J Surg Oncol* 1997; 65: 82-7 (Level III)

13) Todo Y, Sakuragi N, Nishida R, Yamada T, Ebina Y, Yamamoto R, et al. Combined use of magnetic resonance imaging, CA125 assay, histologic type, and histologic grade in the prediction of lymph node metastasis in endometrial carcinoma.

Am J Obstet Gynecol 2003; 188: 1265-72 (Level III)

14) Nomura H, Aoki D, Suzuki N, Susumu N, Suzuki A, Tamada Y, et al. Analysis of clinicopathologic factors predicting para-aortic lymph node metastasis in endometrial cancer. Int J Gynecol Oncol 2006; 16: 799-804 (Level III)

#### **CQ05**

1) Sartori E, Gadducci A, Landoni F, Lissoni A, Maggino T, Zola P, et al. Clinical behavior of 203 stage II endometrial cancer cases: The impact of primary surgical approach and of adjuvant radiation therapy. Int J Gynecol Cancer 2001; 11: 430-7 (Level III)

2) Mariani A, Webb MJ, Keeney GL, Calori G, Podratz KC. Role of wide/radical hysterectomy and pelvic lymph node dissection in endometrial cancer with cervical involvement. Gynecol Oncol 2001; 83: 72-80 (Level III)

3) Leminen A, Forss M, Lehtovirta P. Endometrial adenocarcinoma with clinical evidence of cervical involvement: Accuracy of diagnostic procedures, clinical course, and prognostic factors. Acta Obstet Gynecol Scand 1995; 74: 61-6 (Level III)

4) Paterson E, Spratt D, Tomkiewicz Z, Lewis C, Rathbun P. Management of stage I carcinoma of the uterus. Obstet Gynecol 1982; 59: 755-8 (Level III)

5) Mangioni C, De Palo G, Marubini E, Del Vecchio M. Surgical pathologic staging in apparent stage I endometrial carcinoma. Int J Gynecol Cancer 1993; 3: 373-84 (Level III)

6) Sato R, Jobo T, Kuramoto H. Parametrial spread is a prognostic factor in endometrial carcinoma. Eur J Gynaecol Oncol 2003; 24: 241-5 (Level III)

7) Yura Y, Tauchi K, Koshiyama M, Konishi I, Yura S, Mori T, et al. Parametrial involvement in endometrial carcinomas: Its incidence and correlation with other histological parameters. Gynecol Oncol 1996; 63: 114-9 (Level III)

8) Susumu N, Sagae S, Udagawa Y, Niwa K, Kuramoto H, Satoh S, et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: A Japanese Gynecologic Oncology Group study. Gynecol Oncol 2008; 108: 226-33 (Level II)

#### **CQ06**

1) Takeshima N, Hirai Y, Yano K, Tanaka N, Yamauchi K, Hasumi K. Ovarian metastasis in endometrial carcinoma. Gynecol Oncol 1998; 70: 183-7 (Level III)

2) Boronow RC, Morrow CP, Creasman WT, DiSaia PJ, Silverberg SG, Miller A, et

al. Surgical staging in endometrial cancer: Clinical-pathologic findings of a prospective study. *Obstet Gynecol* 1984; 63: 825-32 (**Level III**)

3) Boente MP, Yordan EL Jr, McIntosh DG, Grendys EC Jr, Orandi YA, Davies S, et al. Prognostic factors and long-term survival in endometrial adenocarcinoma with cervical involvement. *Gynecol Oncol* 1993; 51: 316-22 (**Level III**)

4) Creasman WT, DeGeest K, DiSaia PJ, Zaino RJ. Significance of true surgical pathologic staging: A Gynecologic Oncology Group study. *Am J Obstet Gynecol* 1999; 181: 31-4 (**Level III**)

5) Leminen A, Forss M, Lehtovirta P. Endometrial adenocarcinoma with clinical evidence of cervical involvement: Accuracy of diagnostic procedures, clinical course, and prognostic factors. *Acta Obstet Gynecol Scand* 1995; 74: 61-6 (**Level III**)

6) Sato R, Jobo T, Kuramoto H. Parametrial spread is a prognostic factor in endometrial carcinoma. *Eur J Gynaecol Oncol* 2003; 24: 241-5 (**Level III**)

7) Yura Y, Tauchi K, Koshiyama M, Konishi I, Yura S, Mori T, et al. Parametrial involvement in endometrial carcinomas: Its incidence and correlation with other histological parameters. *Gynecol Oncol* 1996; 63: 114-9 (**Level III**)

8) Yamazawa K, Seki K, Matsui H, Kihara M, Sekiya S. Prognostic factors in young women with endometrial carcinoma: A report of 20 cases and review of literature. *Int J Gynecol Cancer* 2000; 10: 212-22 (**Level III**)

9) Evans-Metcalf ER, Brooks SE, Reale FR, Baker SP. Profile of women 45 years of age and younger with endometrial cancer. *Obstet Gynecol* 1998; 91: 349-54 (**Level III**)

10) Wright JD, Buck AM, Shah M, Burke WM, Schiff PB, Herzog TJ. Safety of ovarian preservation in premenopausal women with endometrial cancer. *J Clin Oncol* 2009; 27: 1214-9 (**Level III**)

11) Gitsch G, Hanzal E, Jensen D, Hacker NF. Endometrial cancer in premenopausal women 45 years and younger. *Obstet Gynecol* 1995; 85: 504-8 (**Level III**)

12) Walsh C, Holschneider C, Hoang Y, Tieu K, Karlan B, Cass I. Coexisting ovarian malignancy in young women with endometrial cancer. *Obstet Gynecol* 2005; 106: 693-9 (**Level III**)

13) Hemminki K, Aaltonen L, Li X. Subsequent primary malignancies after endometrial carcinoma and ovarian carcinoma. *Cancer* 2003; 97: 2432-9 (**Level III**)

14) 坂口 勲, 新田 慎, 宮原 陽, 園田直子, 末永義人, 大竹秀幸, 他. 婦人科臓器重複癌 97 例 (1985~2000 年) の臨床的検討. *産婦治療* 2002; 85: 120-5 (**Level III**)

15) 笹川 基, 田村 希, 塚田清二, 本間 滋, 高橋 威. 子宮体癌における重複癌. *日産婦誌* 2000; 52 : 756-60 (**Level III**)

16) Kamikatahira S, Jobo T, Kuramoto H. Endometrial carcinoma with

synchronous ovarian malignancy—Differentiation between independent and metastatic carcinomas. *Int J Clin Oncol* 1996; 1: 100-8 (**Level III**)

17) Nishimura N, Hachisuga T, Yokoyama M, Iwasaka T, Kawarabayashi T. Clinicopathologic analysis of the prognostic factors in women with coexistence of endometrioid adenocarcinoma in the endometrium and ovary. *J Obstet Gynaecol Res* 2005; 31: 120-6 (**Level III**)

#### **CQ07**

1) Barakat RR, Grigsby PW, Sabbatini P, Zaino RJ. Corpus: Epithelial tumors. In: Hoskins WJ, Perez CA, Young RC eds. *Principles and Practice of Gynecologic Oncology* 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2000; 919-59 (**Level IV**)

2) 日本産科婦人科学会, 日本病理学会, 日本医学放射線学会編. 子宮体癌取扱い規約, 改訂第2版. 東京: 金原出版, 1996; 15-8 (**規約**)

3) 日本癌治療学会編. 日本癌治療学会リンパ節規約. 東京: 金原出版, 2002; 12-6, 35-6 (**規約**)

4) Sato R, Jobo T, Kuramoto H. Parametrial spread is a prognostic factor in endometrial carcinoma. *Eur J Gynaecol Oncol* 2003; 24: 241-5 (**Level III**)

5) 竹島信宏, 梅沢 聡, 清水敬生, 藤本郁野, 山内一弘, 荷見勝彦. 子宮体癌骨盤内リンパ節転移に関する研究. *日産婦誌* 1994; 46: 883-8 (**Level III**)

6) 加藤 清, 堀内晶子, 塩原茂樹, 塩沢丹里, 折井文香, 二階堂敏雄, 他. 鼠径部表皮下リンパ節転移を伴った粘膜内子宮体癌の一例. *日婦病理・コルポスコピー会誌* 1998; 16: 58 (**Level IV**)

7) Scholz HS, Lax S, Petru E, Benedicic C, Winter R. Inguinal lymph node metastasis as the presenting symptom of endometrial cancer: A case report. *Anticancer Res* 2002; 22: 2531-2 (**Level III**)

8) Kaneyasu Y, Okawa T, Yajima M, Saito R, Nakabayashi M, Seshimo A, et al. Stage IVB uterine endometrial cancer successfully salvaged by chemoradiotherapy and surgery. *Int J Clin Oncol* 2003; 8: 60-4 (**Level III**)

9) Katz LA, Andrews SJ, Fanning J. Survival after multimodality treatment for stage IIIC endometrial cancer. *Am J Obstet Gynecol* 2001; 184: 1071-3 (**Level III**)

10) Aalders JG, Abeler V, Kolstad P. Stage IV endometrial carcinoma: A clinical and histopathological study of 83 patients. *Gynecol Oncol* 1984; 17: 75-84 (**Level III**)

#### **CQ08**

1) 青木照明, 平井勝也. 大網切除術. 図説産婦人科 VIEW 16, 卵巣の手術, 桑原慶紀編. 東京: メジカルビュー社, 1995; 88-94 (**Level IV**)



- 2) Greer EJ, Koh W-J, Abu-Rustum N, Bookman MA, Bristow RE, Campos S, et al. NCCN Practice Guidelines in Oncology Version 1. 2008. Uterine Neoplasms. <http://www.nccn.org/professionals/physician> (**Guideline**)
- 3) Saygili U, Kavaz S, Altunyurt S, Uslu T, Koyuncuoglu M, Erten O. Omentectomy, peritoneal biopsy and appendectomy in patients with clinical stage I endometrial carcinoma. *Int J Gynecol Cancer* 2001; 11: 471-4 (**Level III**)
- 4) Chen SS, Spiegel G. Stage I endometrial carcinoma. Role of omental biopsy and omentectomy. *J Reprod Med* 1991; 36: 627-9 (**Level III**)
- 5) Fujiwara H, Saga Y, Takahashi K, Ohwada M, Enomoto A, Konno R, et al. Omental metastases in clinical stage I endometrioid adenocarcinoma. *Int J Gynecol Cancer* 2008; 18: 165-7 (**Level III**)

#### **CQ09**

- 1) Kinkel K, Kaji Y, Yu KK, Segal MR, Lu Y, Powell CB, et al. Radiologic staging in patients with endometrial cancer: A meta-analysis. *Radiology* 1999; 212: 711-8 (**Level II**)
- 2) Nakao Y, Yokoyama M, Hara K, Koyamatsu Y, Yasunaga M, Araki Y, et al. MR imaging in endometrial carcinoma as a diagnostic tool for the absence of myometrial invasion. *Gynecol Oncol* 2006; 102: 343-7 (**Level III**)
- 3) Nagar H, Dobbs S, McClelland HR, Price J, McCluggage WG, Grey A. The diagnostic accuracy of magnetic resonance imaging in detecting cervical involvement in endometrial cancer. *Gynecol Oncol* 2006; 103: 431-4 (**Level III**)
- 4) Ortashi O, Jain S, Emmanuel O, Henry R, Wood A, Evans J. Evaluation of the sensitivity, specificity, positive and negative predictive values of preoperative magnetic resonance imaging for staging endometrial cancer. A prospective study of 100 cases at the Dorset Cancer Centre. *Eur J Obstet Gynecol Reprod Biol* 2008; 137: 232-5 (**Level III**)
- 5) Savelli L, Ceccarini M, Ludovisi M, Fruscella E, Delaco PA, Salizzoni E, et al. Preoperative local staging of endometrial cancer: transvaginal sonography vs. magnetic resonance imaging. *Ultrasound Obstet Gynecol* 2008; 31: 560-6 (**Level III**)
- 6) Manfredi R, Mirk P, Maresca G, Margariti PA, Testa A, Zannoni GF, et al. Local-regional staging of endometrial carcinoma: Role of MR imaging in surgical planning. *Radiology* 2004; 231: 372-8 (**Level III**)
- 7) Koyama T, Tamai K, Togashi K. Staging of carcinoma of the uterine cervix and endometrium. *Eur Radiol* 2007; 17: 2009-19 (**Level IV**)
- 8) Rockall AG, Sohaib SA, Harisinghani MG, Babar SA, Singh N, Jeyarajah AR,

et al. Diagnostic performance of nanoparticle-enhanced magnetic resonance imaging in the diagnosis of lymph node metastases in patients with endometrial and cervical cancer. *J Clin Oncol* 2005; 23: 2813-21 (**Level III**)

9) Suzuki R, Miyagi E, Takahashi N, Sukegawa A, Suzuki A, Koike I, et al. Validity of positron emission tomography using fluoro-2-deoxyglucose for the preoperative evaluation of endometrial cancer. *Int J Gynecol Cancer* 2007; 17: 890-6 (**Level III**)

10) Park JY, Kim EN, Kim DY, Suh DS, Kim JH, Kim YM, et al. Comparison of the validity of magnetic resonance imaging and positron emission tomography/computed tomography in the preoperative evaluation of patients with uterine corpus cancer. *Gynecol Oncol* 2008; 108: 486-92 (**Level III**)

11) Kitajima K, Murakami K, Yamasaki E, Fukasawa I, Inaba N, Kaji Y, et al. Accuracy of 18 F-FDG PET/CT in detecting pelvic and paraaortic lymph node metastasis in patients with endometrial cancer. *AJR Am J Roentgenol* 2008; 190: 1652-8 (**Level III**)

12) Torricelli P, Ferraresi S, Fiocchi F, Ligabue G, Jasonni VM, DiMonte I, et al. 3-T MRI in the preoperative evaluation of depth of myometrial infiltration in endometrial cancer. *AJR Am J Roentgenol* 2008; 190: 489-95 (**Level III**)

13) NCCN practice Guidelines in Oncology Version 1. 2008. Uterine cancers. <http://www.nccn.org/professionals/physician> (**Guideline**)

#### **CQ10**

1) Zorlu CG, Kuscu E, Ergun Y, Aydogdu T, Cobanoglu O, Erdas O. Intraoperative evaluation of prognostic factors in stage I endometrial cancer by frozen section: How reliable? *Acta Obstet Gynecol Scand* 1993; 72: 382-5 (**Level III**)

2) Kayikçioğlu F, Boran N, Meydanlı MM, Tulunay G, Köse FM, Bülbül D. Is frozen-section diagnosis a reliable guide in surgical treatment of stage I endometrial carcinoma? *Acta Oncol* 2002; 41: 444-6 (**Level III**)

3) Kucera E, Kainz C, Reinthaller A, Sliutz G, Leodolter S, Kucera H, et al. Accuracy of intraoperative frozen-section diagnosis in stage I endometrial adenocarcinoma. *Gynecol Obstet Invest* 2000; 49: 62-6 (**Level III**)

4) Quinlivan JA, Petersen RW, Nicklin JL. Accuracy of frozen section for the operative management of endometrial cancer. *BJOG* 2001; 108: 798-803 (**Level III**)

5) Shim JU, Rose PG, Reale FR, Soto H, Tak WK, Hunter RE. Accuracy of frozen-section diagnosis at surgery in clinical stage I and II endometrial carcinoma. *Am J Obstet Gynecol* 1992; 166: 1335-8 (**Level III**)

- 6) Doering DL, Barnhill DR, Weiser EB, Burke TW, Woodward JE, Park RC. Intraoperative evaluation of depth of myometrial invasion in stage I endometrial adenocarcinoma. *Obstet Gynecol* 1989; 74: 930-3 (**Level III**)
- 7) Vorgias G, Hintipas E, Katsoulis M, Kalinoglou N, Dertimas B, Akrivos T. Intraoperative gross examination of myometrial invasion and cervical infiltration in patients with endometrial cancer: Decision-making accuracy. *Gynecol Oncol* 2002; 85: 483-6 (**Level III**)
- 8) Goff BA, Rice LW. Assessment of depth of myometrial invasion in endometrial adenocarcinoma. *Gynecol Oncol* 1990; 38: 46-8 (**Level III**)
- 9) 孫 廷慰, 鄧 豫增, 藏本博行: 子宮体癌の筋層浸潤に関する術中肉眼診断の評価. *日癌治療会誌* 1994; 29: 1942-7 (**Level III**)
- 10) Altintas A, Cosar E, Vardar MA, Demir C, Tuncer I. Intraoperative assessment of depth of myometrial invasion in endometrial carcinoma. *Eur J Gynaecol Oncol* 1999; 20: 329-31 (**Level III**)
- 11) Frumovitz M, Singh DK, Meyer L, Smith DH, Wertheim I, Resnik E, et al. Predictors of final histology in patients with endometrial cancer. *Gynecol Oncol* 2004; 95: 463-8 (**Level III**)
- 12) Case AS, Rocconi RP, Straughn JM Jr, Conner M, Novak L, Wang W, et al. A prospective blinded evaluation of the accuracy of frozen section for the surgical management of endometrial cancer. *Obstet Gynecol* 2006; 108: 1375-9 (**Level III**)
- 13) American College of Obstetricians and Gynecologists. ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: Management of endometrial cancer. *Obstet Gynecol* 2005; 106: 413-25 (**Guideline**)
- 14) Cragun JM, Havrilesky LJ, Calingaert B, Synan I, Secord AA, Soper JT, et al. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. *J Clin Oncol* 2005; 23: 3668-75 (**Level III**)
- 15) Chan JK, Cheung MK, Huh WK, Osann K, Husain A, Teng NN, et al. Therapeutic role of lymph node resection in endometrioid corpus cancer: A study of 12,333 patients. *Cancer* 2006; 107: 1823-30 (**Level III**)
- 16) Chan JK, Wu H, Cheung MK, Shin JY, Osann K, Kapp DS. The outcomes of 27,063 women with unstaged endometrioid uterine cancer. *Gynecol Oncol* 2007; 106: 282-8 (**Level III**)
- 17) Chi DS, Barakat RR, Palayekar MJ, Levine DA, Sonoda Y, Alektiar K, et al. The incidence of pelvic lymph node metastasis by FIGO staging for patients with adequately surgically staged endometrial adenocarcinoma of endometrioid histology. *Int J Gynecol Cancer* 2008; 18: 269-73 (**Level III**)

### CQ11

- 1) Bjornsson BL, Nelson BE, Reale FR, Rose PG. Accuracy of frozen section for lymph node metastasis in patients undergoing radical hysterectomy for carcinoma of the cervix. *Gynecol Oncol* 1993; 51: 50-3 (**Level III**)
- 2) Dixon JM, Mamman U, Thomas J. Accuracy of intraoperative frozen-section analysis of axillary nodes. Edinburgh Breast Unit team. *Br J Surg* 1999; 86: 392-5 (**Level III**)
- 3) Young MP, Kirby RS, O' Donoghue EP, Parkinson MC. Accuracy and cost of intraoperative lymph node frozen sections at radical prostatectomy. *J Clin Pathol* 1999; 52: 925-7 (**Level III**)
- 4) Chao C, Wong SL, Ackermann D, Simpson D, Carter MB, Brown CM, et al. Utility of intraoperative frozen section analysis of sentinel lymph nodes in breast cancer. *Am J Surg* 2001; 182: 609-15 (**Level III**)
- 5) Arango HA, Hoffman MS, Roberts WS, DeCesare SL, Fiorica JV, Drake J. Accuracy of lymph node palpation to determine need for lymphadenectomy in gynecologic malignancies. *Obstet Gynecol* 2000; 95: 553-6 (**Level III**)

### CQ12

- 1) Holub Z, Jabor A, Kliment L. Comparison of two procedures for sentinel lymph node detection in patients with endometrial cancer: A pilot study. *Eur J Gynaecol Oncol* 2002; 23: 53-7 (**Level IV**)
- 2) Altgassen C, Pagenstecher J, Hornung D, Diedrich K, Hornemann A. A new approach to label sentinel nodes in endometrial cancer. *Gynecol Oncol* 2007; 105: 457-61 (**Level III**)
- 3) Lopes LA, Nicolau SM, Baracat FF, Baracat EC, Gonçalves WJ, Santos HV, et al. Sentinel lymph node in endometrial cancer. *Int J Gynecol Cancer* 2007; 17: 1113-7 (**Level III**)
- 4) Niikura H, Okamura C, Utsunomiya H, Yoshinaga K, Akahira J, Ito K, et al. Sentinel lymph node detection in patients with endometrial cancer. *Gynecol Oncol* 2004; 92: 669-74 (**Level III**)
- 5) Niikura H, Okamoto S, Yoshinaga K, Nagase S, Takano T, Ito K, et al. Detection of micrometastases in the sentinel lymph nodes of patients with endometrial cancer. *Gynecol Oncol* 2007; 105: 683-6 (**Level III**)
- 6) Delaloye JF, Pampallona S, Chardonens E, Fiche M, Lehr HA, De Grandi P, et al. Intraoperative lymphatic mapping and sentinel node biopsy using hysteroscopy in patients with endometrial cancer. *Gynecol Oncol* 2007; 106: 89-93 (**Level III**)

- 7) Bats AS, Clément D, Larousserie F, Le Frère-Belda MA, Pierquet-Ghazzar N, Hignette C, et al. Does sentinel node biopsy improve the management of endometrial cancer? Data from 43 patients. *J Surg Oncol* 2008; 97: 141-5 (**Level III**)
- 8) Frumovitz M, Bodurka DC, Broaddus RR, Coleman RL, Sood AK, Gershenson DM, et al. Lymphatic mapping and sentinel node biopsy in women with high-risk endometrial cancer. *Gynecol Oncol* 2007; 104: 100-3 (**Level III**)

### **CQ13**

- 1) Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. *Int J Gynaecol Obstet* 2009; 105: 103-4 (規約)
- 2) Kashimura M, Sugihara K, Toki N, Matsuura Y, Kawagoe T, Kamura T, et al. The significance of peritoneal cytology in uterine cervix and endometrial cancer. *Gynecol Oncol* 1997; 67: 285-90 (**Level II**)
- 3) Obermair A, Geramou M, Tripcony L, Nicklin JL, Perrin L, Crandon AJ. Peritoneal cytology: Impact on disease-free survival in clinical stage I endometrioid adenocarcinoma of the uterus. *Cancer Lett* 2001; 164: 105-10 (**Level III**)
- 4) Konski A, Poulter C, Keys H, Rubin P, Beecham J, Doane K. Absence of prognostic significance, peritoneal dissemination and treatment advantage in endometrial cancer patients with positive peritoneal cytology. *Int J Radiat Oncol Biol Phys* 1988; 14: 49-55 (**Level III**)
- 5) Hirai Y, Fujimoto I, Yamauchi K, Hasumi K, Masubuchi K, Sano Y. Peritoneal fluid cytology and prognosis in patients with endometrial carcinoma. *Obstet Gynecol* 1989; 73: 335-8 (**Level III**)
- 6) Kasamatsu T, Onda T, Katsumata N, Sawada M, Yamada T, Tsunematsu R, et al. Prognostic significance of positive peritoneal cytology in endometrial carcinoma confined to the uterus. *Br J Cancer* 2003; 88: 245-50 (**Level II**)
- 7) Ebina Y, Hareyama H, Sakuragi N, Yamamoto R, Furuya M, Sogame M, et al. Peritoneal cytology and its prognostic value in endometrial carcinoma. *Int Surg* 1997; 82: 244-8 (**Level II**)
- 8) Kadar N, Homesley HD, Malfetano JH. Positive peritoneal cytology is an adverse factor in endometrial carcinoma only if there is other evidence of extrauterine disease. *Gynecol Oncol* 1992; 46: 145-9 (**Level II**)
- 9) Takeshima N, Nishida H, Tabata T, Hirai Y, Hasumi K. Positive peritoneal cytology in endometrial cancer: Enhancement of other prognostic indicators. *Gynecol Oncol* 2001; 82: 470-3 (**Level III**)
- 10) Turner DA, Gershenson DM, Atkinson N, Sneige N, Wharton AT. The

prognostic significance of peritoneal cytology for stage I endometrial cancer. *Obstet Gynecol* 1989; 74: 775-80 (**Level III**)

11) Harouny VR, Sutton GP, Clark SA, Geisler HE, Stehman FB, Ehrlich CE. The importance of peritoneal cytology in endometrial carcinoma. *Obstet Gynecol* 1988; 72: 394-8 (**Level III**)

12) Tebeu PM, Popowski GY, Verkooijen HM, Casals J, Lüdicke F, Zeciri G, et al. Impact of peritoneal cytology on survival of endometrial cancer patients treated with surgery and radiotherapy. *Br J Cancer* 2003; 89: 2023-6 (**Level III**)

13) Mazurka JL, Krepart GV, Lotocki RJ. Prognostic significance of positive peritoneal cytology in endometrial carcinoma. *Am J Obstet Gynecol* 1988; 158: 303-6 (**Level III**)

14) Yazigi R, Piver MS, Blumenson L. Malignant peritoneal cytology as prognostic indicator in stage I endometrial cancer. *Obstet Gynecol* 1983; 62: 359-62 (**Level III**)

15) NCCN practice Guidelines in Oncology Version 1. 2008. Uterine cancers. <http://www.nccn.org/professionals/physician> (**Guideline**)

#### **CQ14**

1) Hasenburg A, Ledet SC, Ardaman T, Levy T, Kieback DG. Evaluation of lymph nodes in squamous cell carcinoma of the cervix: Touch imprint cytology versus frozen section histology. *Int J Gynecol Cancer* 1999; 9: 337-41 (**Level III**)

2) Anastasiadis P, Sivridis E, Koutlaki N, Tamiolakis D, Galazios G, Tsikouras P. The significance of rapid intraoperative cytology in the evaluation of intraperitoneal and retroperitoneal spread of cervical cancer. *Gynecol Oncol* 2002; 84: 102-9 (**Level III**)

3) Kadar N, Homesley HD, Malfetano JH. Positive peritoneal cytology is an adverse factor in endometrial carcinoma only if there is other evidence of extrauterine disease. *Gynecol Oncol* 1992; 46: 145-9 (**Level II**)

4) Takeshima N, Nishida H, Tabata T, Hirai Y, Hasumi K. Positive peritoneal cytology in endometrial cancer: Enhancement of other prognostic indicators. *Gynecol Oncol* 2001; 82: 470-3 (**Level III**)

5) Hirai Y, Fujimoto I, Yamauchi K, Hasumi K, Masubuchi K, Sano Y. Peritoneal fluid cytology and prognosis in patients with endometrial carcinoma. *Obstet Gynecol* 1989; 73: 335-8 (**Level III**)

6) Yanoh K, Takeshima N, Hirai Y, Minami A, Tsuzuku M, Toyoda N, et al. Identification of a high-risk subgroup in cytology-positive stage IIIA endometrial cancer. *Acta Cytol* 2001; 45: 691-6 (**Level III**)

7) 蔵本博行, 上坊敏子, 新井正秀. 子宮体部の悪性腫瘍. F 治療法, i 手術療法. 新女性

**CQ15**

- 1) Malur S, Possover M, Michels W, Schneider A. Laparoscopic—assisted vaginal versus abdominal surgery in patients with endometrial cancer — A prospective randomized trial. *Gynecol Oncol* 2001; 80: 239-44 (Level II)
- 2) Eltabbakh GH. Analysis of survival after laparoscopy in women with endometrial carcinoma. *Cancer* 2002; 95: 1894-901 (Level III)
- 3) Fram KM. Laparoscopically assisted vaginal hysterectomy versus abdominal hysterectomy in stage I endometrial cancer. *Int J Gynecol Cancer* 2002; 12: 57-61 (Level III)
- 4) Nagao S, Fujiwara K, Kagawa R, Kozuka Y, Oda T, Maehata K, et al. Feasibility of extraperitoneal laparoscopic para-aortic and common iliac lymphadenectomy. *Gynecol Oncol* 2006; 103: 732-5 (Level III)
- 5) Litta P, Fracas M, Pozzan C, Merlin F, Saccardi C, Sacco G, et al. Laparoscopic management of early stage endometrial cancer. *Eur J Gynaecol Oncol* 2003; 24: 41-4 (Level III)
- 6) Zapico A, Fuentes P, Grassa A, Arnanz F, Otazua J, Cortés-Prieto J. Laparoscopic-assisted vaginal hysterectomy versus abdominal hysterectomy in stages I and II endometrial cancer. Operating data, follow up and survival. *Gynecol Oncol* 2005; 98: 222-7 (Level III)
- 7) Langebrekke A, Istre O, Hallqvist AC, Hartgill TW, Onsrud M. Comparison of laparoscopy and laparotomy in patients with endometrial cancer. *J Am Assoc Gynecol Laparosc* 2002; 9: 152-7 (Level III)
- 8) Manolitsas TP, McCartney AJ. Total laparoscopic hysterectomy in the management of endometrial carcinoma. *J Am Assoc Gynecol Laparosc* 2002; 9: 54-62 (Level III)
- 9) Cho YH, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH. Laparoscopic management of early uterine cancer: 10-year experience in Asan Medical Center. *Gynecol Oncol* 2007; 106: 585-90 (Level III)
- 10) Kalogiannidis I, Lambrechts S, Amant F, Neven P, Van Gorp T, Vergote I. Laparoscopy-assisted vaginal hysterectomy compared with abdominal hysterectomy in clinical stage I endometrial cancer: Safety, recurrence, and long-term outcome. *Am J Obstet Gynecol* 2007; 196: 248.e1-8 (Level III)
- 11) Sonoda Y, Zerbe M, Smith A, Lin O, Barakat RR, Hoskins WJ. High incidence of positive peritoneal cytology in low-risk endometrial cancer treated by

laparoscopically assisted vaginal hysterectomy. *Gynecol Oncol* 2001; 80: 378-82 (**Level III**)

12) Eltabbakh GH, Mount SL. Laparoscopic surgery does not increase the positive peritoneal cytology among women with endometrial carcinoma. *Gynecol Oncol* 2006; 100: 361-4 (**Level III**)

13) Muntz HG, Goff BA, Madsen BL, Yon JL. Port-site recurrence after laparoscopic surgery for endometrial carcinoma. *Obstet Gynecol* 1999; 93: 807-9 (**Level IV**)

14) NCCN practice Guidelines in Oncology Version 1. 2008. Uterine cancers. <http://www.nccn.org/professionals/physician> (**Guideline**)

### **CQ16**

1) Grigsby PW, Kuske RR, Perez CA, Walz BJ, Camel MH, Kao MS, et al. Medically inoperable stage I adenocarcinoma of the endometrium treated with radiotherapy alone. *Int J Radiat Oncol Biol Phys* 1987; 13: 483-8 (**Level III**)

2) Taghian A, Pernot M, Hoffstetter S, Luporsi E, Bey P. Radiation therapy alone for medically inoperable patients with adenocarcinoma of the endometrium. *Int J Radiat Oncol Biol Phys* 1988; 15: 1135-40 (**Level III**)

3) Lehoczky O, Bősze P, Ungár L, Töttösy B. Stage I endometrial carcinoma: Treatment of nonoperable patients with intracavitary radiation therapy alone. *Gynecol Oncol* 1991; 43: 211-6 (**Level III**)

4) Kupelian PA, Eifel PJ, Tornos C, Burke TW, Delclos L, Oswald MJ. Treatment of endometrial carcinoma with radiation therapy alone. *Int J Radiat Oncol Biol Phys* 1993; 27: 817-24 (**Level III**)

5) Rouanet P, Dubois JB, Gely S, Pourquier H. Exclusive radiation therapy in endometrial carcinoma. *Int J Radiat Oncol Biol Phys* 1993; 26: 223-8 (**Level III**)

6) Chao CK, Grigsby PW, Perez CA, Mutch DG, Herzog T, Camel HM. Medically inoperable stage I endometrial carcinoma: A few dilemmas in radiotherapeutic management. *Int J Radiat Oncol Biol Phys* 1996; 34: 27-31 (**Level III**)

7) Knocke TH, Kucera H, Weidinger B, Höller W, Pötter R. Primary treatment of endometrial carcinoma with high-dose-rate brachytherapy: Results of 12 years of experience with 280 patients. *Int J Radiat Oncol Biol Phys* 1997; 37: 359-65 (**Level III**)

8) 兼安祐子. 子宮体癌. 放射線治療計画ガイドライン 2008. 日本放射線専門医会・医会, 日本放射線腫瘍学会, 日本医学放射線学会編. 埼玉: 日本放射線科専門医会・医会事務局. 2008; 225-32 (**Guideline**)



## Chapter 3 Postoperative Adjuvant Therapy

### I. Radiotherapy

#### CQ17

- 1) Aalders J, Abeler V, Kolstad P, Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: Clinical and histopathologic study of 540 patients. *Obstet Gynecol* 1980; 56: 419-27 (**Level II**)
- 2) Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Wárlám-Rodenhuis CC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: Multicentre randomised trial. PORTEC Study Group. *Post Operative Radiation Therapy in Endometrial Carcinoma*. *Lancet* 2000; 355: 1404-11 (**Level II**)
- 3) Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: A Gynecologic Oncology Group study. *Gynecol Oncol* 2004; 92: 744-51 (**Level II**)
- 4) Kong A, Simera I, Collingwood M, Williams C, Kitchener H. Cochrane Gynaecological Cancer Group. Adjuvant radiotherapy for stage I endometrial cancer: Systematic review and meta-analysis. *Ann Oncol* 2007; 18: 1595-604 (**Level I**)
- 5) Johnson N, Cornes P. Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer: Systematic review and meta-analysis. *BJOG* 2007; 114: 1313-20 (**Level I**)
- 6) Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group study. *Cancer* 1987; 60: 2035-41 (**Level III**)
- 7) Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A Gynecologic Oncology Group study. *Gynecol Oncol* 1991; 40: 55-65 (**Level III**)
- 8) Zaino RJ, Kurman RJ, Diana KL, Morrow CP. Pathologic models to predict outcome for women with endometrial adenocarcinoma: The importance of the distinction between surgical stage and clinical stage—A Gynecologic Oncology Group study. *Cancer* 1996; 77: 1115-21 (**Level III**)
- 9) Creutzberg CL, van Putten WL, Wárlám-Rodenhuis CC, van den Bergh AC, de Winter KA, Koper PC, et al. Outcome of high-risk stage IC, Grade 3, compared with stage I endometrial carcinoma patients: The Postoperative Radiation Therapy in Endometrial Carcinoma Trial. *J Clin Oncol* 2004; 22: 1234-41 (**Level III**)

- 10) Greven KM, Lanciano RM, Herbert SH, Hogan PE. Analysis of complications in patients with endometrial carcinoma receiving adjuvant irradiation. *Int J Radiat Oncol Biol Phys* 1991; 21: 919-23 **(Level III)**
- 11) Irwin C, Levin W, Fyles A, Pintilie M, Manchul L, Kirkbride P. The role of adjuvant radiotherapy in carcinoma of the endometrium—Results in 550 patients with pathologic stage I disease. *Gynecol Oncol* 1998; 70: 247-54 **(Level III)**
- 12) MacLeod C, Fowler A, Duval P, D' Costa I, Dalrymple C, Elliott P, et al. Adjuvant high-dose rate brachytherapy with or without external beam radiotherapy post-hysterectomy for endometrial cancer. *Int J Gynecol Cancer* 1999; 9: 247-55 **(Level III)**
- 13) Greven KM, D' Agostino RB Jr, Lanciano RM, Corn BW. Is there a role for a brachytherapy vaginal cuff boost in the adjuvant management of patients with uterine-confined endometrial cancer? *Int J Radiat Oncol Biol Phys* 1998; 42: 101-4 **(Level III)**
- 14) Rossi PJ, Jani AB, Horowitz IR, Johnstone PA. Adjuvant brachytherapy removes survival disadvantage of local disease extension in stage IIIC endometrial cancer: A SEER registry analysis. *Int J Radiat Oncol Biol Phys* 2008; 70: 134-8 **(Level III)**

#### **CQ18**

- 1) Carey MS, O' Connell GJ, Johanson CR, Goodyear MD, Murphy KJ, Daya DM, et al. Good outcome associated with a standardized treatment protocol using selective postoperative radiation in patients with clinical stage I adenocarcinoma of the endometrium. *Gynecol Oncol* 1995; 57: 138-44 **(Level III)**
- 2) Elliott P, Green D, Coates A, Krieger M, Russell P, Coppleson M, et al. The efficacy of postoperative vaginal irradiation in preventing vaginal recurrence in endometrial cancer. *Int J Gynecol Cancer* 1994; 4: 84-93 **(Level III)**
- 3) Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A Gynecologic Oncology Group study. *Gynecol Oncol* 1991; 40: 55-65 **(Level III)**
- 4) Zaino RJ, Kurman RJ, Diana KL, Morrow CP. Pathologic models to predict outcome for women with endometrial adenocarcinoma: The importance of the distinction between surgical stage and clinical stage—A Gynecologic Oncology Group study. *Cancer* 1996; 77: 1115-21 **(Level III)**

- 5) Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Wárlám-Rodenhuis CC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: Multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. *Lancet* 2000; 355: 1404-11 (**Level II**)
- 6) Weiss E, Hirnle P, Arnold-Bofinger H, Hess CF, Bamberg M. Adjuvant vaginal high-dose-rate afterloading alone in endometrial carcinoma: Patterns of relapse and side effects following low-dose therapy. *Gynecol Oncol* 1998; 71: 72-6 (**Level III**)
- 7) Eltabbakh GH, Piver MS, Hempling RE, Shin KH. Excellent long-term survival and absence of vaginal recurrences in 332 patients with low-risk stage I endometrial adenocarcinoma treated with hysterectomy and vaginal brachytherapy without formal staging lymph node sampling: Report of a prospective trial. *Int J Radiat Oncol Biol Phys* 1997; 38: 373-80 (**Level III**)
- 8) Petereit DG, Tannehill SP, Grosen EA, Hartenbach EM, Schink JC. Outpatient vaginal cuff brachytherapy for endometrial cancer. *Int J Gynecol Cancer* 1999; 9: 456-62 (**Level III**)
- 9) Ng TY, Perrin LC, Nicklin JL, Cheuk R, Crandon AJ. Local recurrence in high-risk node-negative stage I endometrial carcinoma treated with postoperative vaginal vault brachytherapy. *Gynecol Oncol* 2000; 79: 490-4 (**Level III**)
- 10) Fanning J. Long-term survival of intermediate risk endometrial cancer (stage IG3, IC, II) treated with full lymphadenectomy and brachytherapy without teletherapy. *Gynecol Oncol* 2001; 82: 371-4 (**Level III**)
- 11) Chadha M, Nanavati PJ, Liu P, Fanning J, Jacobs A. Patterns of failure in endometrial carcinoma stage IB grade 3 and IC patients treated with postoperative vaginal vault brachytherapy. *Gynecol Oncol* 1999; 75: 103-7 (**Level III**)
- 12) Anderson JM, Stea B, Hallum AV, Rogoff E, Childers J. High-dose-rate postoperative vaginal cuff irradiation alone for stage IB and IC endometrial cancer. *Int J Radiat Oncol Biol Phys* 2000; 46: 417-25 (**Level III**)
- 13) Straughn JM, Huh WK, Orr JW Jr, Kelly FJ, Roland PY, Gold MA, et al. Stage IC adenocarcinoma of the endometrium: Survival comparisons of surgically staged patients with and without adjuvant radiation therapy. *Gynecol Oncol* 2003; 89: 295-300 (**Level III**)
- 14) Rittenberg PV, Lotocki RJ, Heywood MS, Jones KD, Krepart GV. High-risk surgical stage 1 endometrial cancer: Outcomes with vault brachytherapy alone. *Gynecol Oncol* 2003; 89: 288-94 (**Level III**)

- 15) Ackerman I, Malone S, Thomas G, Franssen E, Balogh J, Dembo A. Endometrial carcinoma—relative effectiveness of adjuvant irradiation vs therapy reserved for relapse. *Gynecol Oncol* 1996; 60: 177-83 (**Level III**)
- 16) Touboul E, Belkacémi Y, Buffat L, Deniaud-Alexandre E, Lefranc JP, Lhuillier P, et al. Adenocarcinoma of the endometrium treated with combined irradiation and surgery: Study of 437 patients. *Int J Radiat Oncol Biol Phys* 2001; 50: 81-97 (**Level III**)
- 17) Nout RA, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, et al. Vaginal brachytherapy versus external beam pelvic radiotherapy for high-intermediate risk endometrial cancer: Results of the randomized PORTEC-2 trial. *J Clin Oncol* 2008; 26 (May 20 suppl; abstr LBA5503) (**Level II**)

### **CQ19**

- 1) Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A Gynecologic Oncology Group study. *Gynecol Oncol* 1991; 40: 55-65 (**Level II**)
- 2) Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer: A Gynecologic Oncology Group study. *Cancer* 1987; 60: 2035-41 (**Level III**)
- 3) Corn BW, Lanciano RM, D'agostino R, Kiggundu E, Dunton CJ, Purser P, et al. The relationship of local and distant failure from endometrial cancer: Defining a clinical paradigm. *Gynecol Oncol* 1997; 66: 411-6 (**Level III**)
- 4) Mundt AJ, Murphy KT, Rotmensch J, Waggoner SE, Yamada SD, Connell PP, et al. Surgery and postoperative radiation therapy in FIGO Stage III C endometrial carcinoma. *Int J Radiat Oncol Biol Phys* 2001; 50: 1154-60 (**Level III**)
- 5) McMeekin DS, Lashbrook D, Gold M, Johnson G, Walker JL, Mannel R. Analysis of FIGO Stage IIIc endometrial cancer patients. *Gynecol Oncol* 2001; 81: 273-8 (**Level III**)
- 6) Greven KM, Curran WJ Jr, Whittington R, Fanning J, Randall ME, Wilder J, et al. Analysis of failure patterns in stage III endometrial carcinoma and therapeutic implications. *Int J Radiat Oncol Biol Phys* 1989; 17: 35-9 (**Level III**)
- 7) Grigsby PW, Perez CA, Kuske RR, Kao MS, Galakatos AE. Results of therapy, analysis of failures, and prognostic factors for clinical and pathologic stage III adenocarcinoma of the endometrium. *Gynecol Oncol* 1987; 27: 44-57 (**Level III**)
- 8) Stewart KD, Martinez AA, Weiner S, Podratz K, Stromberg JS, Schray M, et al. Ten-year outcome including patterns of failure and toxicity for adjuvant whole

abdominopelvic irradiation in high-risk and poor histologic feature patients with endometrial carcinoma. *Int J Radiat Oncol Biol Phys* 2002; 54: 527-35 (**Level III**)

9) Smith RS, Kapp DS, Chen Q, Teng NN. Treatment of high-risk uterine cancer with whole abdominopelvic radiation therapy. *Int J Radiat Oncol Biol Phys* 2000; 48: 767-78 (**Level III**)

10) Randall ME, Spirtos NM, Dvoretzky P. Whole abdominal radiotherapy versus combination chemotherapy with doxorubicin and cisplatin in advanced endometrial carcinoma (phase III): Gynecologic Oncology Group study No.122. *J Natl Cancer Inst Monogr* 1995; 19: 13-5 (**Level III**)

11) Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: A Gynecologic Oncology Group study. *J Clin Oncol* 2006; 24: 36-44 (**Level II**)

#### **CQ20**

1) De Naeyer B, De Meerleer G, Braems S, Vakaet L, Huys J. Collagen vascular diseases and radiation therapy: A critical review. *Int J Radiat Oncol Biol Phys* 1999; 44: 975-80 (**Level III**)

2) Chon BH, Loeffler JS. The effect of nonmalignant systemic disease on tolerance to radiation therapy. *Oncologist* 2002; 7: 136-43 (**Level III**)

3) Morris MM, Powell SN. Irradiation in the setting of collagen vascular disease: Acute and late complications. *J Clin Oncol* 1997; 15: 2728-35 (**Level III**)

4) Fleck R, McNeese MD, Ellerbroek NA, Hunter TA, Holmes FA. Consequences of breast irradiation in patients with pre-existing collagen vascular disease. *Int J Radiat Oncol Biol Phys* 1989; 17: 829-33 (**Level III**)

5) Teo P, Tai TH, Choy D. Nasopharyngeal carcinoma with dermatomyositis. *Int J Radiat Oncol Biol Phys* 1989; 16: 471-4 (**Level III**)

6) Ross JG, Hussey DH, Mayr NA, Davis CS. Acute and late reactions to radiation therapy in patients with collagen vascular diseases. *Cancer* 1993; 71: 3744-52 (**Level III**)

7) Phan C, Mindrum M, Silverman C, Paris K, Spanos W. Matched-control retrospective study of the acute and late complications in patients with collagen vascular diseases treated with radiation therapy. *Cancer J* 2003; 9: 461-6 (**Level III**)

8) Willett CG, Ooi CJ, Zietman AL, Menon V, Goldberg S, Sands BE, et al. Acute and late toxicity of patients with inflammatory bowel disease undergoing irradiation for

abdominal and pelvic neoplasms. *Int J Radiat Oncol Biol Phys* 2000; 46: 995-8 (**Level III**)

9) Song DY, Lawrie WT, Abrams RA, Kafonek DR, Bayless TM, Welsh JS, et al. Acute and late radiotherapy toxicity in patients with inflammatory bowel disease. *Int J Radiat Oncol Biol Phys* 2001; 51: 455-9 (**Level III**)

## **II. Chemotherapy and Hormone Therapy**

### **CQ21**

1) Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: A Gynecologic Oncology Group study. *J Clin Oncol* 2006; 24: 36-44 (**Level II**)

2) Susumu N, Sagae S, Udagawa Y, Niwa K, Kuramoto H, Satoh S, et al. Randomized Phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: A Japanese Gynecologic Oncology Group study. *Gynecol Oncol* 2008; 108: 226-33 (**Level II**)

3) Maggi R, Lissoni A, Spina F, Melpignano M, Zola P, Favalli G, et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: Results of a randomised trial. *Br J Cancer* 2006; 95: 266-71 (**Level II**)

4) Hogberg T, Rosenberg P, Kristensen G, de Oliveira CF, de Pont Christensen R, Sorbe B, et al. A randomized phase-III study on adjuvant treatment with radiation (RT) ± chemotherapy (CT) in early-stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991). *J Clin Oncol* 2007; 25 (June 20 suppl; abstr 5503) (**Level II**)

5) Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A Gynecologic Oncology Group study. *Gynecol Oncol* 1991; 40: 55-65 (**Level III**)

6) Boronow RC, Morrow CP, Creasman WT, Disaia PJ, Silverberg SG, Miller A, et al. Surgical staging in endometrial cancer: Clinical-pathologic findings of a prospective study. *Obstet Gynecol* 1984; 63: 825-32 (**Level III**)

### **CQ22**

1) Muss HB. Chemotherapy of metastatic endometrial cancer. *Semin Oncol* 1994; 21: 107-13 (**Level III**)

- 2) Ball HG, Blessing JA, Lentz SS, Mutch DG. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: A Gynecologic Oncology Group study. *Gynecol Oncol* 1996; 62: 278-81 (**Level III**)
- 3) Lissoni A, Zanetta G, Losa G, Gabriele A, Parma G, Mangioni C. Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer. *Ann Oncol* 1996; 7: 861-3 (**Level III**)
- 4) Katsumata N, Noda K, Nozawa S, Kitagawa R, Nishimura R, Yamaguchi S, et al. Phase II trial of docetaxel in advanced or metastatic endometrial cancer: A Japanese Cooperative Study. *Br J Cancer* 2005; 93: 999-1004 (**Level III**)
- 5) Hirai Y, Hasumi K, Onose R, Kuramoto H, Kuzuya K, Hatae M, et al. Phase II trial of 3-h infusion of paclitaxel in patients with adenocarcinoma of endometrium: Japanese Multicenter Study Group. *Gynecol Oncol* 2004; 94: 471-6 (**Level III**)
- 6) Morrow CP, Bundy BN, Homesley HD, Creasman WT, Hornback NB, Kurman RJ, et al. Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: A Gynecologic Oncology Group study. *Gynecol Oncol* 1990; 36: 166-71 (**Level III**)
- 7) Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: A Gynecologic Oncology Group study. *J Clin Oncol* 2006; 24: 36-44 (**Level II**)
- 8) A randomized phase III study of tumor volume directed pelvic plus or minus para-aortic irradiation followed by cisplatin and doxorubicin or cisplatin, doxorubicin and paclitaxel for advanced endometrial carcinoma. Phase III, GOG study #184. GOG ホームページ <http://www.gog.org/> (**Level IV**)
- 9) JGOG ホームページ <http://www.jgog.gr.jp/> (**Level IV**)
- 10) Michener CM, Peterson G, Kulp B, Webster KD, Markman M. Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma. *J Cancer Res Clin Oncol* 2005; 131: 581-4 (**Level III**)
- 11) Akram T, Maseelall P, Fanning J. Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer. *Am J Obstet Gynecol* 2005; 192: 1365-7 (**Level III**)
- 12) Hoskins PJ, Swenerton KD, Pike JA, Wong F, Lim P, Aquino-Parsons C, et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: A phase II study. *J Clin Oncol* 2001; 19: 4048-53 (**Level III**)

### CQ23

- 1) Lewis GC Jr, Slack NH, Mortel R, Bross ID. Adjuvant progestogen therapy in the primary definitive treatment of endometrial cancer. *Gynecol Oncol* 1974; 2: 368-76  
(Level III)
- 2) McDonald RR, Thorogood J, Mason MK. A randomized trial of progestogens in the primary treatment of endometrial carcinoma. *Br J Obstet Gynaecol* 1988; 95: 166-74  
(Level II)
- 3) Vergote I, Kjørstad K, Abeler V, Kolstad P. A randomized trial of adjuvant progestagen in early endometrial cancer. *Cancer* 1989; 64: 1011-6 (Level II)
- 4) De Palo G, Mangioni C, Periti P, Del Vecchio M, Marubini E. Treatment of FIGO (1971) stage I endometrial carcinoma with intensive surgery, radiotherapy and hormonal therapy according to pathological prognostic groups: Long-term results of a randomised multicentre study. *Eur J Cancer* 1993; 29: 1133-40 (Level II)
- 5) 佐藤信二, 矢嶋 聡, 野澤志朗, 宇田川康博, 寺島芳輝, 西谷 巖, 他. 子宮体癌に対する補助化学療法としての MPA の有効性に関する研究—子宮体がん化学療法第二次研究. *Oncol Chemother* 1996; 12: 172-81 (Level III)
- 6) COSA-NZ-UK Endometrial Cancer Study Groups. Adjuvant medroxyprogesterone acetate in high-risk endometrial cancer. *Int J Gynecol Cancer* 1998; 8: 387-91 (Level III)
- 7) von Minckwitz G, Loibl S, Brunnert K, Kreienberg R, Melchert F, Mösch R, et al. Adjuvant endocrine treatment with medroxyprogesterone acetate or tamoxifen in stage I and II endometrial cancer—A multicentre, open, controlled, prospectively randomised trial. *Eur J Cancer* 2002; 38: 2265-71 (Level II)
- 8) Martin-Hirsch PPL, Jarvis GG, Kitchener HC, Lilford R. Progestagens for endometrial cancer. *Cochrane Library*, Issue 4, New York: John Wiley & Sons Inc, 2003  
(Level I)



## Chapter 4 Post-treatment Follow-up

### CQ24

- 1) Reddoch JM, Burke TW, Morris M, Tornos C, Levenback C, Gershenson DM. Surveillance for recurrent endometrial carcinoma: Development of a follow-up scheme. *Gynecol Oncol* 1995; 59: 221-5 (**Level III**)
- 2) Shumsky AG, Stuart GC, Brasher PM, Nation JG, Robertson DI, Sangkarat S. An evaluation of routine follow-up of patients treated for endometrial carcinoma. *Gynecol Oncol* 1994; 55: 229-33 (**Level III**)
- 3) Owen P, Duncan ID. Is there any value in the long term follow up of women treated for endometrial cancer? *Br J Obstet Gynecol* 1996; 103: 710-3 (**Level III**)
- 4) Agboola OO, Grunfeld E, Coyle D, Perry GA. Costs and benefits of routine follow-up after curative treatment for endometrial cancer. *CMAJ* 1997; 157: 879-86 (**Level III**)
- 5) Morice P, Levy-Piedbois C, Ajaj S, Pautier P, Haie-Meder C, Lhomme C, et al. Value and cost evaluation of routine follow-up for patients with clinical stage I/II endometrial cancer. *Eur J Cancer* 2001; 37: 985-90 (**Level III**)
- 6) 井上正樹. 子宮体癌治療後のフォローアップの個別化. *産婦の実際* 2000; 49: 1607-13 (**Level IV**)
- 7) Sartori E, Pasinetti B, Carrara L, Gambino A, Odicino F, Pecorelli S. Pattern of failure and value of follow-up procedures in endometrial and cervical cancer patients. *Gynecol Oncol* 2007; 107: 241-7 (**Level III**)
- 8) 丹野純香, 伊藤 潔, 片平敦子, 岡村智佳子, 八重樫伸生, 岡村州博. わが教室における子宮体癌の管理. *産婦治療* 2002; 85: 683-9 (**Level IV**)
- 9) Lurain JR, Rice BL, Rademaker AW, Poggensee LE, Schink JC, Miller DS. Prognostic factors associated with recurrence in clinical stage I adenocarcinoma of the endometrium. *Obstet Gynecol* 1991; 78: 63-9 (**Level III**)
- 10) Podczaski E, Kaminski P, Gurski K, MacNeil C, Stryker JA, Singapuri K, et al. Detection and patterns of treatment failure in 300 consecutive cases of “early” endometrial cancer after primary surgery. *Gynecol Oncol* 1992; 47: 323-7 (**Level III**)
- 11) Mandell LR, Nori D, Hilaris B. Recurrent stage I endometrial carcinoma: Results of treatment and prognostic factors. *Int J Radiat Oncol Biol Phys* 1985; 11: 1103-9 (**Level III**)
- 12) Kuten A, Grigsby PW, Perez CA, Fineberg B, Garcia DM, Simpson JR. Results of radiotherapy in recurrent endometrial carcinoma: A retrospective analysis of 51 patients. *Int J Radiat Oncol Biol Phys* 1989; 17: 29-34 (**Level III**)

13) Smith CJ, Heeren M, Nicklin JL, Perrin LC, Land R, Crandon AJ, et al. Efficacy of routine follow-up in patients with recurrent uterine cancer. *Gynecol Oncol* 2007; 107: 124-9 (**Level III**)

### CQ25

1) Duk JM, Aalders JG, Fleuren GJ, de Bruijn HW. CA125: A useful marker in endometrial carcinoma. *Am J Obstet Gynecol* 1986; 155: 1097-102 (**Level III**)

2) Matorras R, Rodríguez-Escudero FJ, Diez J, Genollá J, Cruz Fombellida J, Ruibal A. Monitoring endometrial adenocarcinoma with a four tumor marker combination. CA 125, squamous cell carcinoma antigen, CA 19.9 and CA 15.3. *Acta Obstet Gynecol Scand* 1992; 71: 458-64 (**Level III**)

3) Takeshima N, Shimizu Y, Umezawa S, Hirai Y, Chen JT, Fujimoto I, et al. Combined assay of serum levels of CA125 and CA19-9 in endometrial carcinoma. *Gynecol Oncol* 1994; 54: 321-6 (**Level III**)

4) Rose PG, Sommers RM, Reale FR, Hunter RE, Fournier L, Nelson BE. Serial serum CA125 measurements for evaluation of recurrence in patients with endometrial carcinoma. *Obstet Gynecol* 1994; 84: 12-6 (**Level III**)

5) 佐藤賢一郎, 水内英充, 森 泰宏, 岡村直樹, 遠藤俊明, 伊東英樹, 他. 子宮体癌の再発管理に血中 CA125 値は有用か? *日産婦誌* 1995 ; 47 : 917-24 (**Level IV**)

6) 青木大輔, 片岡史夫, 進 伸幸, 野澤志朗. 腫瘍マーカーによる子宮体癌診断の要点. *産婦の実際* 2002 ; 51 : 949-57 (**Level III**)

7) Shumsky AG, Stuart GC, Brasher PM, Nation JG, Robertson DI, Sangkarat S. An evaluation of routine follow-up of patients treated for endometrial carcinoma. *Gynecol Oncol* 1994; 55: 229-33 (**Level III**)

8) Owen P, Duncan ID. Is there any value in the long term follow up of women treated for endometrial cancer? *Br J Obstet Gynecol* 1996; 103: 710-3 (**Level III**)

9) Agboola OO, Grunfeld E, Coyle D, Perry GA. Costs and benefits of routine follow-up after curative treatment for endometrial cancer. *CMAJ* 1997; 157: 879-86 (**Level III**)

10) Morice P, Levy-Piedbois C, Ajaj S, Pautier P, Haie-Meder C, Lhomme C, et al. Value and cost evaluation of routine follow-up for patients with clinical stage I/II endometrial cancer. *Eur J Cancer* 2001; 37: 985-90 (**Level III**)

11) Reddoch JM, Burke TW, Morris M, Tornos C, Levenback C, Gershenson DM. Surveillance for recurrent endometrial carcinoma: Development of a follow-up scheme. *Gynecol Oncol* 1995; 59: 221-5 (**Level III**)

## CQ26

- 1) Mandell LR, Nori D, Hilaris B. Recurrent stage I endometrial carcinoma: Results of treatment and prognostic factors. *Int J Radiat Oncol Biol Phys* 1985; 11: 1103-9 (**Level III**)
- 2) Kuten A, Grigsby PW, Perez CA, Fineberg B, Garcia DM, Simpson JR. Results of radiotherapy in recurrent endometrial carcinoma: A retrospective analysis of 51 patients. *Int J Radiat Oncol Biol Phys* 1989; 17: 29-34 (**Level III**)
- 3) Lurain JR, Rice BL, Rademaker AW, Poggensee LE, Schink JC, Miller DS. Prognostic factors associated with recurrence in clinical stage I adenocarcinoma of the endometrium. *Obstet Gynecol* 1991; 78: 63-9 (**Level III**)
- 4) Podczaski E, Kaminski P, Gurski K, MacNeil C, Stryker JA, Singapuri K, et al. Detection and patterns of treatment failure in 300 consecutive cases of “early” endometrial cancer after primary surgery. *Gynecol Oncol* 1992; 47: 323-7 (**Level III**)
- 5) Reddoch JM, Burke TW, Morris M, Tornos C, Levenback C, Gershenson DM. Surveillance for recurrent endometrial carcinoma: Development of a follow-up scheme. *Gynecol Oncol* 1995; 59: 221-5 (**Level III**)
- 6) Shumsky AG, Stuart GC, Brasher PM, Nation JG, Robertson DI, Sangkarat S. An evaluation of routine follow-up of patients treated for endometrial carcinoma. *Gynecol Oncol* 1994; 55: 229-33 (**Level III**)
- 7) Morice P, Levy-Piedbois C, Ajaj S, Pautier P, Haie-Meder C, Lhomme C, et al. Value and cost evaluation of routine follow-up for patients with clinical stage I/II endometrial cancer. *Eur J Cancer* 2001; 37: 985-90 (**Level III**)
- 8) Mundt AJ, McBride R, Rotmensch J, Waggoner SE, Yamada SD, Connell PP. Significant pelvic recurrence in high-risk pathologic stage I—IV endometrial carcinoma patients after adjuvant chemotherapy alone: Implications for adjuvant radiation therapy. *Int J Radiat Oncol Biol Phys* 2001; 50: 1145-53 (**Level III**)
- 9) Stewart KD, Martinez AA, Weiner S, Podratz K, Stromberg JS, Schray M, et al. Ten-year outcome including patterns of failure and toxicity for adjuvant whole abdominopelvic irradiation in high-risk and poor histologic feature patients with endometrial carcinoma. *Int J Radiat Oncol Biol Phys* 2002; 54: 527-35 (**Level III**)
- 10) Sartori E, Laface B, Gadducci A, Maggino T, Zola P, Landoni F, et al. Factors influencing survival in endometrial cancer relapsing patients: A Cooperating Task Force (CTF) study. *Int J Gynecol Cancer* 2003; 13: 458-65 (**Level III**)
- 11) Agboola OO, Grunfeld E, Coyle D, Perry GA. Costs and benefits of routine follow-up after curative treatment for endometrial cancer. *CMAJ* 1997; 157: 879-86 (**Level III**)

12) Owen P, Duncan ID. Is there any value in the long term follow up of women treated for endometrial cancer? *Br J Obstet Gynecol* 1996; 103: 710-3 (**Level III**)

### **CQ27**

1) Mandell LR, Nori D, Hilaris B. Recurrent stage I endometrial carcinoma: Results of treatment and prognostic factors. *Int J Radiat Oncol Biol Phys* 1985; 11: 1103-9 (**Level III**)

2) Shumsky AG, Stuart GC, Brasher PM, Nation JG, Robertson DI, Sangkarat S. An evaluation of routine follow-up of patients treated for endometrial carcinoma. *Gynecol Oncol* 1994; 55: 229-33 (**Level III**)

3) Morice P, Levy-Piedbois C, Ajaj S, Pautier P, Haie-Meder C, Lhomme C, et al. Value and cost evaluation of routine follow-up for patients with clinical stage I/II endometrial cancer. *Eur J Cancer* 2001; 37: 985-90 (**Level III**)

4) Stewart KD, Martinez AA, Weiner S, Podratz K, Stromberg JS, Schray M, et al. Ten-year outcome including patterns of failure and toxicity for adjuvant whole abdominopelvic irradiation in high-risk and poor histologic feature patients with endometrial carcinoma. *Int J Radiat Oncol Biol Phys* 2002; 54: 527-35 (**Level III**)

5) Henricksen E. The lymphatic dissemination in endometrial carcinoma. A study of 188 necropsies. *Am J Obstet Gynecol* 1975; 123: 570-6 (**Level III**)

6) Podczaski E, Kaminski P, Gurski K, MacNeil C, Stryker JA, Singapuri K, et al. Detection and patterns of treatment failure in 300 consecutive cases of "early" endometrial cancer after primary surgery. *Gynecol Oncol* 1992; 47: 323-7 (**Level III**)

7) Reddoch JM, Burke TW, Morris M, Tornos C, Levenback C, Gershenson DM. Surveillance for recurrent endometrial carcinoma: Development of a follow-up scheme. *Gynecol Oncol* 1995; 59: 221-5 (**Level III**)

8) Agboola OO, Grunfeld E, Coyle D, Perry GA. Costs and benefits of routine follow-up after curative treatment for endometrial cancer. *CMAJ* 1997; 157: 879-86 (**Level III**)

9) Thorvinger B. Diagnostic and interventional radiology in gynecologic neoplasms. *Acta Radiol Suppl* 1992; 378: 93-108 (**Level III**)

10) Belhocine T, De Barsy C, Hustinx R, Willems-Foidart J. Usefulness of (18)F-FDG PET in the post-therapy surveillance of endometrial carcinoma. *Eur J Nucl Med Mol Imaging* 2002; 29: 1132-9 (**Level III**)

11) Belhocine T. An appraisal of 18F-FDG PET imaging in post-therapy surveillance of uterine cancers: Clinical evidence and a research proposal. *Int J Gynecol Cancer* 2003; 13: 228-33 (**Level III**)

- 12) Sugimura K, Okizuka H. Postsurgical pelvis: Treatment follow-up. Radiol Clin North Am 2002; 40: 659-80 (**Level III**)
- 13) Connor JP, Andrews JI, Anderson B, Buller RE. Computed tomography in endometrial carcinoma. Obstet Gynecol 2000; 95: 692-6 (**Level III**)

## Chapter 5 Treatment of Advanced and Recurrent Cancer

### CQ28

- 1) Aoki Y, Kase H, Watanabe M, Sato T, Kurata H, Tanaka K. Stage III endometrial cancer: Analysis of prognostic factors and failure patterns after adjuvant chemotherapy. *Gynecol Oncol* 2001; 83: 1-5 (**Level III**)
- 2) Ayhan A, Taskiran C, Celik C, Aksu T, Yuce K. Surgical stage III endometrial cancer: Analysis of treatment outcomes, prognostic factors and failure patterns. *Eur J Gynecol Oncol* 2002; 23: 553-6 (**Level III**)
- 3) Mundt AJ, Murphy KT, Rotmensch J, Waggoner SE, Yamada SD, Connell PP. Surgery and postoperative radiation therapy in FIGO stage IIIC endometrial carcinoma. *Int J Radiat Oncol Biol Phys* 2001; 50: 1154-60 (**Level III**)
- 4) Otsuka I, Kubota T, Aso T. Lymphadenectomy and adjuvant therapy in endometrial carcinoma: Role of adjuvant chemotherapy. *Br J Cancer* 2002; 87: 377-80 (**Level III**)
- 5) McMeekin DS, Lashbrook D, Gold M, Johnson G, Walker JL, Mannel R. Analysis of FIGO stage IIIc endometrial cancer patients. *Gynecol Oncol* 2001; 81: 273-8 (**Level III**)
- 6) Bristow RE, Zahurak ML, Alexander CJ, Zellars RC, Montz FJ. FIGO stage IIIc endometrial carcinoma: Resection of macroscopic nodal disease and other determinants of survival. *Int J Gynecol Cancer* 2003; 13: 664-72 (**Level III**)
- 7) Behbakht K, Yordan EL, Casey C, DeGeest K, Massad LS, Kirschner CV, et al. Prognostic indicators of survival in advanced endometrial cancer. *Gynecol Oncol* 1994; 55: 363-7 (**Level III**)
- 8) 衛藤貴子, 岡留雅夫, 齋藤俊章, 入江智子, 植田多恵子, 小川伸二, 他. 子宮体癌における臨床的諸問題—進行子宮体癌に対する積極的手術療法に関する検討. *日産婦九州連合会誌* 2002 ; 11 : 73-6 (**Level III**)
- 9) NCCN Practice Guidelines in Oncology v.1. 2008. Uterine cancers. <http://www.nccn.org/professionals/physician> (**Guideline**)

### CQ29

- 1) Goff BA, Goodman A, Muntz HG, Fuller AF Jr, Nikrui N, Rice LW. Surgical stage IV endometrial carcinoma: A study of 47 cases. *Gynecol Oncol* 1994; 52: 237-40 (**Level III**)
- 2) McMeekin DS, Garcia M, Gold M, Johnson G, Walker J, Mannel R. Stage IVB endometrial cancer: Survival, recurrence, and role of surgery. *Am Soci Clin Oncol* 2001 Annual Meeting, abstract # 821 (**Level III**)

- 3) Chi DS, Welshinger M, Venkatraman ES, Barakat RR. The role of surgical cytoreduction in stage IV endometrial carcinoma. *Gynecol Oncol* 1997; 67: 56-60 (**Level III**)
- 4) Bristow RE, Zerbe MJ, Rosenshein NB, Grumbine FC, Montz FJ. Stage IVB endometrial carcinoma: The role of cytoreductive surgery and determinants of survival. *Gynecol Oncol* 2000; 78: 85-91 (**Level III**)
- 5) Ayhan A, Taskiran C, Celik C, Yuce K, Kucukali T. The influence of cytoreductive surgery on survival and morbidity in stage IVB endometrial cancer. *Int J Gynecol Cancer* 2002; 12: 448-53 (**Level III**)
- 6) 衛藤貴子, 岡留雅夫, 齋藤俊章, 入江智子, 植田多恵子, 小川伸二, 他. 子宮体癌における臨床的諸問題—進行子宮体癌に対する積極的手術療法に関する検討. *日産婦九州連合会誌* 2002; 11: 73-6 (**Level III**)
- 7) Bristow RE, Duska LR, Montz FJ. The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma. *Gynecol Oncol* 2001; 81: 92-9 (**Level III**)
- 8) Geisler JP, Geisler HE, Melton ME, Wiemann MC. What staging surgery should be performed on patients with uterine papillary serous carcinoma? *Gynecol Oncol* 1999; 74: 465-7 (**Level III**)
- 9) Campagnutta E, Giorda G, Piero GD, Sopracordevole F, Visentin MC, Martella L, et al. Surgical treatment of recurrent endometrial carcinoma. *Cancer* 2004; 100: 89-96 (**Level III**)

### **CQ30**

- 1) Le TD, Yamada SD, Rutgers JL, DiSaia PJ. Complete response of a stage IV uterine papillary serous carcinoma to neoadjuvant chemotherapy with taxol and carboplatin. *Gynecol Oncol* 1999; 73: 461-3 (**Level IV**)
- 2) Fujiwaki R, Takahashi K, Kitao M. Decrease in tumor volume and histologic response to intraarterial neoadjuvant chemotherapy in patients with cervical and endometrial adenocarcinoma. *Gynecol Oncol* 1997; 65: 258-64 (**Level IV**)
- 3) Resnik E, Taxy JB. Neoadjuvant chemotherapy in uterine papillary serous carcinoma. *Gynecol Oncol* 1996; 62: 123-7 (**Level III**)
- 4) Kaneyasu Y, Okawa T, Yajima M, Saito R, Nakabayashi M, Seshimo A, et al. Stage IVB uterine endometrial cancer successfully salvaged by chemoradiotherapy and surgery. *Int J Clin Oncol* 2003; 8: 60-4 (**Level III**)

- 5) Despierre E, Moerman P, Vergote I, Amant F. Is there a role for neoadjuvant chemotherapy in the treatment of stage IV serous endometrial carcinoma? *Int J Gynecol Cancer* 2006; 16: 273-7 (**Level III**)
- 6) Grigsby PW, Perez CA, Camel HM, Kao MS, Galakatos AE. Stage II carcinoma of the endometrium: Results of therapy and prognostic factors. *Int J Radiat Oncol Biol Phys* 1985; 11: 1915-23 (**Level III**)
- 7) Kinsella TJ, Bloomer WD, Lavin PT, Knapp RC. Stage II endometrial carcinoma: 10-year follow-up of combined radiation and surgical treatment. *Gynecol Oncol* 1980; 10: 290-7 (**Level III**)
- 8) Greven K, Olds W. Radiotherapy in the management of endometrial carcinoma with cervical involvement. *Cancer* 1987; 60: 1737-40 (**Level III**)

### **CQ31**

- 1) 片渕秀隆. 再発子宮内膜癌. *日産婦誌* 2005; 57 : N219-22 (**Level IV**)
- 2) Morris M, Alvarez RD, Kinney WK, Wilson TO. Treatment of recurrent adenocarcinoma of the endometrium with pelvic exenteration. *Gynecol Oncol* 1996; 60: 288-91 (**Level III**)
- 3) Scarabelli C, Campagnutta E, Giorda G, DePiero G, Sopracordevole F, Quaranta M, et al. Maximal cytoreductive surgery as a reasonable therapeutic alternative for recurrent endometrial carcinoma. *Gynecol Oncol* 1998; 70: 90-3 (**Level III**)
- 4) Barakat RR, Goldman NA, Patel DA, Venkatraman ES, Curtin JP. Pelvic exenteration for recurrent endometrial cancer. *Gynecol Oncol* 1999; 75: 99-102 (**Level III**)
- 5) Campagnutta E, Giorda G, De Piero G, Sopracordevole F, Visentin MC, Martella L, et al. Surgical treatment of recurrent endometrial carcinoma. *Cancer* 2004; 100: 89-96 (**Level III**)
- 6) Otsuka I, Ono I, Akamatsu H, Sunamori M, Aso T. Pulmonary metastasis from endometrial carcinoma. *Int J Gynecol Cancer* 2002; 12: 208-13 (**Level III**)
- 7) Fuller AF Jr, Scannell JG, Wilkins EW Jr. Pulmonary resection for metastases from gynecologic cancers: Massachusetts General Hospital experience, 1943-1982. *Gynecol Oncol* 1985; 22: 174-80 (**Level III**)



### CQ32

- 1) Barakat RR, Grigsby PW, Sabbatini P, Zaino RJ. Corpus: Epithelial tumors. In: Hoskins WJ, Perez CA, Young RC eds, Principles and Practice of Gynecologic Oncology. 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2000; 919-59 (**Level IV**)
- 2) Tropé C, Johnson JE, Simonsen E, Christiansen H, Cavallin-Ståhl E, Horváth G. Treatment of recurrent endometrial adenocarcinoma with a combination of doxorubicin and cisplatin. *Am J Obstet Gynecol* 1984; 149: 379-81 (**Level III**)
- 3) Dunton CJ, Pfeifer SM, Braitman LE, Morgan MA, Carlson JA, Mikuta J. Treatment of advanced and recurrent endometrial cancer with cisplatin, doxorubicin and cyclophosphamide. *Gynecol Oncol* 1991; 41: 113-6 (**Level III**)
- 4) Apro MS, van Wijk FH, Bolis G, Chevallier B, van der Burg ME, Poveda A, et al. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: Definitive results of a randomised study (55872) by the EORTC Gynecological Cancer Group. *Ann Oncol* 2003; 14: 441-8 (**Level II**)
- 5) Thigpen JT, Brady MF, Homesley HD, Malfetano J, DuBeshter B, Burger RA, et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: A Gynecologic Oncology Group study. *J Clin Oncol* 2004; 22: 3902-8 (**Level II**)
- 6) Ball HG, Blessing JA, Lentz SS, Mutch DG. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of endometrium: A Gynecologic Oncology Group study. *Gynecol Oncol* 1996; 62: 278-81 (**Level III**)
- 7) Lincoln S, Blessing JA, Lee RB, Rocereto TF. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: A Gynecologic Oncology Group study. *Gynecol Oncol* 2003; 88: 277-81 (**Level III**)
- 8) Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: A Gynecologic Oncology Group study. *J Clin Oncol* 2004; 22: 2159-66 (**Level II**)
- 9) Carey MS, Gawlik C, Fung-Kee-Fung M, Chambers A, Oliver T. Systematic review of systemic therapy for advanced or recurrent endometrial cancer. *Gynecol Oncol* 2006; 101: 158-67 (**Level I**)
- 10) Humber CE, Tierney JF, Symonds RP, Collingwood M, Kirwan J, Williams C, et al. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: A systematic review of Cochrane collaboration. *Ann Oncol* 2007; 18: 409-20 (**Level I**)

### CQ33

- 1) Horton J, Begg CB, Arseneault J, Bruckner H, Creech R, Hahn RG. Comparison of adriamycin with cyclophosphamide in patients with advanced endometrial cancer. *Cancer Treat Rep* 1978; 62: 159-61 (**Level II**)
- 2) Thigpen JT, Buchsbaum HJ, Mangan C, Blessing JA. Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. *Cancer Treat Rep* 1979; 63: 21-7 (**Level III**)
- 3) Thigpen JT, Blessing JA, DiSaia PJ, Yordan E, Carson LF, Evers C. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. *J Clin Oncol* 1994; 12: 1408-14 (**Level II**)
- 4) Aapro MS, Van Wijk FH, Bolis G, Chevallier B, van der Burg ME, Poveda A, et al. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: Definitive results of a randomised study (55872) by the EORTC Gynecological Cancer Group. *Ann Oncol* 2003; 14: 441-8 (**Level II**)
- 5) Tropé C, Johnson JE, Simonsen E, Christiansen H, Cavallin-Ståhl E, Horváth G. Treatment of recurrent endometrial adenocarcinoma with a combination of doxorubicin and cisplatin. *Am J Obstet Gynecol* 1984; 149: 379-81 (**Level III**)
- 6) Dunton CJ, Pfeifer SM, Braitman LE, Morgan MA, Carlson JA, Mikutta J. Treatment of advanced or recurrent endometrial cancer with cisplatin, doxorubicin and cyclophosphamide. *Gynecol Oncol* 1991; 41: 113-6 (**Level III**)
- 7) Ball HG, Blessing JA, Lentz SS, Mutch DG. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of endometrium: A Gynecologic Oncology Group study. *Gynecol Oncol* 1996; 62: 278-81 (**Level III**)
- 8) Lincoln S, Blessing JA, Lee RB, Rocereto TF. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: A Gynecologic Oncology Group study. *Gynecol Oncol* 2003; 88: 277-81 (**Level III**)
- 9) Hirai Y, Hasumi K, Onose R, Kuramoto H, Kuzuya K, Hatae M, et al. Phase II trial of 3-h infusion of paclitaxel in patients with adenocarcinoma of endometrium: Japanese Multicenter Study Group. *Gynecol Oncol* 2004; 94: 471-6 (**Level III**)
- 10) Katsumata N, Noda K, Nozawa S, Kitagawa R, Nishimura R, Yamaguchi S, et al. Phase II trial of docetaxel in advanced or metastatic endometrial cancer: A Japanese Cooperative Study. *Br J Cancer* 2005; 93: 999-1004 (**Level III**)
- 11) Hoskins PJ, Swenerton KD, Pike JA, Wong F, Lim P, Aquino-Parsons C, et al. Paclitaxel and carboplatin, alone or with irradiation in advanced or recurrent endometrial cancer: A phase II study. *J Clin Oncol* 2001; 19: 4048-53 (**Level III**)

- 12) Bafaloukos D, Aravantinos G, Samonis G, Katsifis G, Bakoyiannis C, Skarlos D, et al. Carboplatin, methotrexate and 5-fluorouracil in combination with medroxyprogesterone acetate (JMF-M) in the treatment of advanced or recurrent endometrial carcinoma: A Hellenic Cooperative Oncology Group study. *Oncology* 1999; 56: 198-201 (**Level III**)
- 13) Pectasides D, Xiros N, Papaxoinis G, Pectasides E, Sykiotis C, Koumarianou A, et al. Carboplatin and paclitaxel in advanced or metastatic endometrial cancer. *Gynecol Oncol* 2008; 109: 250-4 (**Level III**)
- 14) Papadimitriou CA, Bafaloukos D, Bozas G, Kalofonos H, Kosmidis P, Aravantinos G, et al. Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: A Hellenic Co-operative Oncology Group (HeCOG) study. *Gynecol Oncol* 2008; 110: 87-92 (**Level III**)
- 15) Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: A Gynecologic Oncology Group study. *J Clin Oncol* 2004;22:2159-66 (**Level II**)
- 16) Nomura H, Aoki D, Takahashi F, Katsumata N, Watanabe Y, Konishi I, et al. Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: Japanese Gynecologic Oncology Group trial (JGOG2041). *Proc Am Soc Clin Oncol* 2008; 26: # 16526 (**Level II**)

#### **CQ34**

- 1) Shiohara S, Ohara M, Itoh K, Shiozawa T, Konishi I. Successful treatment with stereotactic radiosurgery for brain metastases of endometrial carcinoma: A case report and review of the literature. *Int J Gynecol Cancer* 2003; 13: 71-6 (**Level III**)
- 2) Landgren RC, Fletcher GH, Delclos L, Wharton JT. Irradiation of endometrial cancer in patients with medical contraindication to surgery or with unresectable lesions. *Am J Roentgenol* 1976; 126: 148-54 (**Level III**)
- 3) Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Wárlám-Rodenhuis CC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: Multicentre randomised trial. PORTEC Study Group. *Post operative radiation therapy in endometrial carcinoma. Lancet* 2000; 355: 1404-11 (**Level II**)

- 4) Ackerman I, Malone S, Thomas G, Franssen E, Balogh J, Dembo A. Endometrial carcinoma—relative effectiveness of adjuvant irradiation vs therapy reserved for relapse. *Gynecol Oncol* 1996; 60: 177-83 (**Level III**)
- 5) Jhingran A, Burke TW, Eifel PJ. Definitive radiotherapy for patients with isolated vaginal recurrence of endometrial carcinoma after hysterectomy. *Int J Radiat Oncol Biol Phys* 2003; 56: 1366-72 (**Level III**)
- 6) Boulware RJ, Caderao JB, Delclos L, Wharton JT, Peters LJ. Whole pelvis megavoltage irradiation with single doses of 1000 rad to palliate advanced gynecologic cancers. *Int J Radiat Oncol Biol Phys* 1979; 5: 333-8 (**Level III**)
- 7) Spanos WJ Jr, Wasserman T, Meoz R, Sala J, Kong J, Stetz J. Palliation of advanced pelvic malignant disease with large fraction pelvic radiation and misonidazole: Final report of RTOG phase I/II study. *Int J Radiat Oncol Biol Phys* 1987; 13: 1479-82 (**Level III**)
- 8) Onsrud M, Hagen B, Strickert T. 10-Gy single-fraction pelvic irradiation for palliation and life prolongation in patients with cancer of the cervix and corpus uteri. *Gynecol Oncol* 2001; 82: 167-71 (**Level III**)
- 9) Halle JS, Rosenman JG, Varia MA, Fowler WC, Walton LA, Currie JL. 1000 cGy single dose palliation for advanced carcinoma of the cervix or endometrium. *Int J Radiat Oncol Biol Phys* 1986; 12: 1947-50 (**Level III**)
- 10) Spanos W Jr, Guse C, Perez C, Grigsby P, Doggett RL, Poulter C. Phase II study of multiple daily fractionations in the palliation of advanced pelvic malignancies: Preliminary report of RTOG 8502. *Int J Radiat Oncol Biol Phys* 1989; 17: 659-61 (**Level III**)
- 11) Aalders JG, Abeler V, Kolstad P. Clinical (stage III) as compared to subclinical intrapelvic extrauterine tumor spread in endometrial carcinoma: A clinical and histopathological study of 175 patients. *Gynecol Oncol* 1984; 17: 64-74 (**Level III**)
- 12) Greven KM, Curran WJ Jr, Whittington R, Fanning J, Randall ME, Wilder J, et al. Analysis of failure patterns in stage III endometrial carcinoma and therapeutic implications. *Int J Radiat Oncol Biol Phys* 1989; 17: 35-9 (**Level III**)
- 13) Tong D, Gillick L, Hendrickson FR. The palliation of symptomatic osseous metastases. Final results of the study by the Radiation Therapy Oncology Group. *Cancer* 1982; 50: 893-9 (**Level III**)
- 14) Nielsen OS, Munro AJ, Tannock IF. Bone metastases: Pathophysiology and management policy. *J Clin Oncol* 1991; 9: 509-24 (**Level III**)

### CQ35

- 1) Kauppila A. Oestrogen and progesterone receptors as prognostic indicators in endometrial cancer. A review of the literature. *Acta Oncol* 1989; 28: 561-6 (**Level III**)
- 2) Quinn MA, Campbell JJ. Tamoxifen therapy in advanced/recurrent endometrial carcinoma. *Gynecol Oncol* 1989; 32: 1-3 (**Level III**)
- 3) Whitney CW, Brunetto VL, Zaino RJ, Lentz SS, Sorosky J, Armstrong DK, et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: A Gynecologic Oncology Group study. *Gynecol Oncol* 2004; 92: 4-9 (**Level III**)
- 4) Fiorica JV, Brunetto VL, Hanjani P, Lentz SS, Mannel R, Andersen W; Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: A Gynecologic Oncology Group study. *Gynecol Oncol* 2004; 92: 10-4 (**Level III**)
- 5) Singh M, Zaino RJ, Filiaci VJ, Leslie KK. Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: A Gynecologic Oncology Group study. *Gynecol Oncol* 2007; 106: 325-33 (**Level III**)
- 6) Thigpen JT, Brady MF, Alvarez RD, Adelson MD, Homesley HD, Manetta A, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: A dose-response study by the Gynecologic Oncology Group. *J Clin Oncol* 1999; 17: 1736-44 (**Level II**)
- 7) Cohen CJ, Bruckner HW, Deppe G, Blessing JA, Homesley H, Lee JH, et al. Multidrug treatment of advanced and recurrent endometrial carcinoma: A Gynecologic Oncology Group study. *Obstet Gynecol* 1984; 63: 719-26 (**Level II**)
- 8) Horton J, Elson P, Gordon P, Hahn R, Creech R. Combination chemotherapy for advanced endometrial cancer. An evaluation of three regimens. *Cancer* 1982; 49: 2441-5 (**Level III**)
- 9) Cornelison TL, Baker TR, Piver MS, Driscoll DL. Cisplatin, adriamycin, etoposide, megestrol acetate versus melphalan, 5-fluorouracil, medroxyprogesterone acetate in the treatment of endometrial carcinoma. *Gynecol Oncol* 1995; 59: 243-8 (**Level III**)
- 10) Pinelli DM, Fiorica JV, Roberts WS, Hoffman MS, Nicosia SV, Cavanagh D. Chemotherapy plus sequential hormonal therapy for advanced and recurrent endometrial carcinoma: A phase II study. *Gynecol Oncol* 1996; 60: 462-7 (**Level III**)

## Chapter 6 Fertility-Preserving Treatment

### CQ36

- 1) Kinkel K, Kaji Y, Yu KK, Segal MR, Lu Y, Powell CB, et al. Radiologic staging in patients with endometrial cancer: A meta-analysis. *Radiology* 1999; 212: 711-8 (**Level II**)
- 2) Gitsch G, Hanzal E, Jensen D, Hacker NF. Endometrial cancer in premenopausal women 45 years and younger. *Obstet Gynecol* 1995; 85: 504-8 (**Level III**)
- 3) Evans-Metcalf ER, Brooks SE, Reale FR, Baker SP. Profile of women 45 years of age and younger with endometrial cancer. *Obstet Gynecol* 1998; 91: 349-54 (**Level III**)
- 4) Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. *Obstet Gynecol* 1997; 90: 434-40 (**Level IV**)
- 5) Kim YB, Holschneider CH, Ghosh K, Nieberg RK, Montz FJ. Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature. *Cancer* 1997; 79: 320-7 (**Level IV**)
- 6) Gotlieb WH, Beiner ME, Shalmon B, Korach Y, Segal Y, Zmira N, et al. Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer. *Obstet Gynecol* 2003; 102: 718-25 (**Level IV**)
- 7) Jadoul P, Donnez J. Conservative treatment may be beneficial for young women with atypical endometrial hyperplasia or endometrial adenocarcinoma. *Fertil Steril* 2003; 80: 1315-24 (**Level III**)
- 8) Kaku T, Yoshikawa H, Tsuda H, Sakamoto A, Fukunaga M, Kuwabara Y, et al. Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: Central pathologic review and treatment outcome. *Cancer Lett* 2001; 167: 39-48 (**Level III**)
- 9) Imai M, Jobo T, Sato R, Kawaguchi M, Kuramoto H. Medroxyprogesterone acetate therapy for patients with adenocarcinoma of the endometrium who wish to preserve the uterus-usefulness and limitations. *Eur J Gynaecol Oncol* 2001; 22: 217-20 (**Level III**)
- 10) Utsunomiya H, Suzuki T, Ito K, Moriya T, Konno R, Sato S, et al. The correlation between the response to progestogen treatment and the expression of progesterone receptor B and 17beta-hydroxysteroid dehydrogenase type 2 in human endometrial carcinoma. *Clin Endocrinol (Oxf)* 2003; 58: 696-703 (**Level III**)
- 11) Niwa K, Tagami K, Lian Z, Onogi K, Mori H, Tamaya T. Outcome of fertility-preserving treatment in young women with endometrial carcinomas. *BJOG* 2005; 112: 317-20 (**Level III**)

- 12) Yahata T, Fujita K, Aoki Y, Tanaka K. Long-term conservative therapy for endometrial adenocarcinoma in young women. *Hum Reprod* 2006; 21: 1070-5 (**Level III**)
- 13) Yamazawa K, Hirai M, Fujito A, Nishi H, Terauchi F, Ishikura H, et al. Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer. *Hum Reprod* 2007; 22: 1953-8 (**Level III**)
- 14) Minaguchi T, Nakagawa S, Takazawa Y, Nei T, Horie K, Fujiwara T, et al. Combined phospho-Akt and PTEN expressions associated with post-treatment hysterectomy after conservative progestin therapy in complex atypical hyperplasia and stage Ia, G1 adenocarcinoma of the endometrium. *Cancer Lett* 2007; 248: 112-22 (**Level III**)
- 15) Kamoi S, Ohaki Y, Mori O, Kurose K, Fukunaga M, Takeshita T. Serial histologic observation of endometrial adenocarcinoma treated with high-dose progestin until complete disappearance of carcinomatous foci—review of more than 25 biopsies from five patients. *Int J Gynecol Cancer* 2008; 18: 1305-14 (**Level III**)
- 16) Wang CB, Wang CJ, Huang HJ, Hsueh S, Chou HH, Soong YK, et al. Fertility-preserving treatment in young patients with endometrial adenocarcinoma. *Cancer* 2002; 94: 2192-8 (**Level III**)
- 17) Ushijima K, Yahata H, Yoshikawa H, Konishi I, Yasugi T, Saito T, et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. *J Clin Oncol* 2007; 25: 2798-803 (**Level III**)

### **CQ37**

- 1) Wang CB, Wang CJ, Huang HJ, Hsueh S, Chou HH, Soong YK, et al. Fertility-preserving treatment in young patients with endometrial adenocarcinoma. *Cancer* 2002; 94: 2192-8 (**Level III**)
- 2) Ushijima K, Yahata H, Yoshikawa H, Konishi I, Yasugi T, Saito T, et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. *J Clin Oncol* 2007; 25: 2798-803 (**Level II**)
- 3) Kaku T, Yoshikawa H, Tsuda H, Sakamoto A, Fukunaga M, Kuwabara Y, et al. Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: Central pathologic review and treatment outcome. *Cancer Lett* 2001; 167: 39-48 (**Level III**)

- 4) Mitsushita J, Toki T, Kato K, Fujii S, Konishi I. Endometrial carcinoma remaining after term pregnancy following conservative treatment with medroxyprogesterone acetate. *Gynecol Oncol* 2000; 79: 129-32 (**Level IV**)
- 5) Jadoul P, Donnez J. Conservative treatment may be beneficial for young women with atypical endometrial hyperplasia or endometrial adenocarcinoma. *Fertil Steril* 2003; 80: 1315-24 (**Level III**)
- 6) Niwa K, Tagami K, Lian Z, Onogi K, Mori H, Tamaya T. Outcome of fertility-preserving treatment in young women with endometrial carcinomas. *BJOG* 2005; 112: 317-20 (**Level III**)
- 7) Yahata T, Fujita K, Aoki Y, Tanaka K. Long-term conservative therapy for endometrial adenocarcinoma in young women. *Hum Reprod* 2006; 21: 1070-5 (**Level III**)
- 8) Yamazawa K, Hirai M, Fujito A, Nishi H, Terauchi, F, Ishikura H, et al. Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer. *Hum Reprod* 2007; 22: 1953-8 (**Level III**)

### CQ38

- 1) Thigpen JT, Brady MF, Alvarez RD, Adelson MD, Homesley HD, Manetta A, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: A dose-response study by the Gynecologic Oncology Group. *J Clin Oncol* 1999; 17: 1736-44 (**Level II**)
- 2) Ushijima K, Yahata H, Yoshikawa H, Konishi I, Yasugi T, Saito T, et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. *J Clin Oncol* 2007; 25: 2798-803 (**Level II**)
- 3) 佐藤信二, 矢嶋 聡, 野澤志朗, 宇田川康博, 寺島芳輝, 西谷 巖, 他, 子宮体癌に対する補助化学療法としてのMPAの有効性に関する研究. 子宮体がん化学療法第二次研究. *Oncol Chemother* 1996; 12: 172-81 (**Level III**)

### CQ39

- 1) Jadoul P, Donnez J. Conservative treatment may be beneficial for young women with atypical endometrial hyperplasia or endometrial adenocarcinoma. *Fertil Steril* 2003; 80: 1315-24 (**Level III**)



- 2) Mitsushita J, Toki T, Kato K, Fujii S, Konishi I. Endometrial carcinoma remaining after term pregnancy following conservative treatment with medroxyprogesterone acetate. *Gynecol Oncol* 2000; 79: 129-32 (**Level IV**)
- 3) Kaku T, Yoshikawa H, Tsuda H, Sakamoto A, Fukunaga M, Kuwabara Y, et al. Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: Central pathologic review and treatment outcome. *Cancer Lett* 2001; 167: 39-48 (**Level III**)
- 4) Lowe MP, Cooper BC, Sood AK, Davis WA, Syrop CH, Sorosky JI. Implementation of assisted reproductive technologies following conservative management of FIGO grade I endometrial adenocarcinoma and/or complex hyperplasia with atypia. *Gynecol Oncol* 2003; 91: 569-72 (**Level IV**)
- 5) Ushijima K, Yahata H, Yoshikawa H, Konishi I, Yasugi T, Saito T, et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. *J Clin Oncol* 2007; 25: 2798-803 (**Level III**)
- 6) Yahata T, Fujita K, Aoki Y, Tanaka K. Long-term conservative therapy for endometrial adenocarcinoma in young women. *Hum Reprod* 2006; 21: 1070-5 (**Level III**)

#### **CQ40**

- 1) Wang CB, Wang CJ, Huang HJ, Hsueh S, Chou HH, Soong YK, et al. Fertility-preserving treatment in young patients with endometrial adenocarcinoma. *Cancer* 2002; 94: 2192-8 (**Level III**)
- 2) Ushijima K, Yahata H, Yoshikawa H, Konishi I, Yasugi T, Saito T, et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. *J Clin Oncol* 2007; 25: 2798-803 (**Level III**)
- 3) Evans-Metcalf ER, Brooks SE, Reale FR, Baker SP. Profile of women 45 years of age and younger with endometrial cancer. *Obstet Gynecol* 1998; 91: 349-54 (**Level III**)
- 4) Gitsch G, Hanzal E, Jensen D, Hacker NF. Endometrial cancer in premenopausal women 45 years and younger. *Obstet Gynecol* 1995; 85: 504-8 (**Level III**)

## Chapter 7 Atypical Endometrial Hyperplasia

### CQ41

- 1) Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. *Obstet Gynecol* 1997; 90: 434-40 (**Level IV**)
- 2) Kaku T, Yoshikawa H, Tsuda H, Sakamoto A, Fukunaga M, Kuwabara Y, et al. Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: Central pathologic review and treatment outcome. *Cancer Lett* 2001; 167: 39-48 (**Level III**)
- 3) Jobo T, Kawaguchi M, Imai M, Kuramoto H. Treatment for complex atypical hyperplasia of the endometrium. *Eur J Gynaecol Oncol* 2001; 22: 365-8 (**Level III**)
- 4) Ushijima K, Yahata H, Yoshikawa H, Konishi I, Yasugi T, Saito T, et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. *J Clin Oncol* 2007; 25: 2798-803 (**Level II**)
- 5) Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. *Cancer* 1985; 56: 403-12 (**Level III**)
- 6) Baak JP, ø rbo A, van Diest PJ, Jiwa M, de Bruin P, Broeckaert M, et al. Prospective multicenter evaluation of the morphometric D-score for prediction of the outcome of endometrial hyperplasias. *Am J Surg Pathol* 2001; 25: 930-5 (**Level III**)
- 7) Jobo T, Takeoka K, Kuramoto H. Study on the long term follow-up of endometrial hyperplasia. *Int J Clin Oncol* 1996; 1: 163-9 (**Level III**)
- 8) Jobo T, Imai M, Kawaguchi M, Kenmochi M, Kuramoto H. Successful conservative treatment of endometrial carcinoma permitting subsequent pregnancy: Report of two cases. *Eur J Gynaecol Oncol* 2000; 21: 119-22 (**Level IV**)

### CQ42

- 1) Kurman RJ, Norris HJ. Evaluation of criteria for distinguishing atypical endometrial hyperplasia from well-differentiated carcinoma. *Cancer* 1982; 49: 2547-59 (**Level III**)
- 2) Dunton CJ, Baak JP, Palazzo JP, van Diest PJ, McHugh M, Widra EA. Use of computerized morphometric analyses of endometrial hyperplasias in the prediction of coexistent cancer. *Am J Obstet Gynecol* 1996; 174: 1518-21 (**Level III**)
- 3) Trimble CL, Kauderer J, Zaino R, Silverberg S, Lim PC, Burke JJ 2nd, et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical

endometrial hyperplasia: A Gynecologic Oncology Group study. *Cancer* 2006; 106: 812-9  
(**Level III**)

4) Zaino RJ, Kauderer J, Trimble CL, Silverberg SG, Curtin JP, Lim PC, et al.  
Reproducibility of the diagnosis of atypical endometrial hyperplasia: A Gynecologic  
Oncology Group study. *Cancer* 2006; 106: 804-11 (**Level III**)

## Chapter 8 Non endometrioid types

### CQ43

- 1) Sakuragi N, Hareyama H, Todo Y, Yamada H, Yamamoto R, Fujino T, et al. Prognostic significance of serous and clear cell adenocarcinoma in surgically staged endometrial carcinoma. *Acta Obstet Gynecol Scand* 2000; 79: 311-6 (**Level III**)
- 2) Geisler JP, Geisler HE, Melton ME, Wiemann MC. What staging surgery should be performed on patients with uterine papillary serous carcinoma? *Gynecol Oncol* 1999; 74: 465-7 (**Level III**)
- 3) Slomovitz BM, Burke TW, Eifel PJ, Ramondetta LM, Silva EG, Jhingran A, et al. Uterine papillary serous carcinoma (UPSC): A single institution review of 129 cases. *Gynecol Oncol* 2003; 91: 463-9 (**Level III**)
- 4) Goff BA, Kato D, Schmidt RA, Ek M, Ferry JA, Muntz HG, et al. Uterine papillary serous carcinoma: Patterns of metastatic spread. *Gynecol Oncol* 1994; 54: 264-8 (**Level III**)
- 5) Chan JK, Loizzi V, Youssef M, Osann K, Rutgers J, Vasilev SA, et al. Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium. *Gynecol Oncol* 2003; 90: 181-5 (**Level III**)
- 6) Gehrig PA, Groben PA, Fowler WC Jr, Walton LA, Van Le L. Noninvasive papillary serous carcinoma of the endometrium. *Obstet Gynecol* 2001; 97: 153-7 (**Level III**)
- 7) Thomas MB, Mariani A, Cliby WA, Keeney GA, Podratz KC, Dowdy SC. Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma. *Gynecol Oncol* 2007; 107: 186-9 (**Level III**)
- 8) Tay EH, Ward BG. The treatment of uterine papillary serous carcinoma (UPSC): Are we doing the right thing? *Int J Gynecol Cancer* 1999; 9: 463-9 (**Level III**)
- 9) Thomas M, Mariani A, Wright JD, Madarek EO, Powell MA, Mutch DG, et al. Surgical management and adjuvant therapy for patients with uterine clear cell carcinoma: A multi-institutional review. *Gynecol Oncol* 2008; 108: 293-7 (**Level III**)

### CQ44

- 1) Hamilton CA, Liou WS, Osann K, Berman ML, Husain A, Teng NN, et al. Impact of adjuvant therapy on survival of patients with early-stage uterine papillary serous carcinoma. *Int J Radiat Oncol Biol Phys* 2005; 63: 839-44 (**Level III**)
- 2) Kelly MG, O' Malley DM, Hui P, McAlpine J, Yu H, Rutherford TJ, et al. Improved survival in surgical stage I patients with uterine papillary serous carcinoma

(UPSC) treated with adjuvant platinum-based chemotherapy. *Gynecol Oncol* 2005; 98: 353-9 (**Level III**)

3) Kwon JS, Abrams J, Sugimoto A, Carey MS. Is adjuvant therapy necessary for stage IA and IB uterine papillary serous carcinoma and clear cell carcinoma after surgical staging? *Int J Gynecol Cancer* 2008; 18: 820-4 (**Level III**)

4) Mehta N, Yamada SD, Rotmensch J, Mundt AJ. Outcome and pattern of failure in pathologic stage I-II papillary serous carcinoma of the endometrium: Implications for adjuvant radiation therapy. *Int J Radiat Oncol Biol Phys* 2003; 57: 1004-9 (**Level III**)

5) Turner BC, Knisely JP, Kacinski BM, Haffty BG, Gumbs AA, Roberts KB, et al. Effective treatment of stage I uterine papillary serous carcinoma with high dose-rate vaginal apex radiation (<sup>192</sup>Ir) and chemotherapy. *Int J Radiat Oncol Biol Phys* 1998; 40: 77-84 (**Level III**)

6) Dietrich CS 3rd, Modesitt SC, DePriest PD, Ueland FR, Wilder J, Reedy MB, et al. The efficacy of adjuvant platinum-based chemotherapy in stage I uterine papillary serous carcinoma (UPSC). *Gynecol Oncol* 2005; 99: 557-63 (**Level III**)

7) Thomas M, Mariani A, Wright JD, Madarek EO, Powell MA, Mutch DG, et al. Surgical management and adjuvant therapy for patients with uterine clear cell carcinoma: A multi-institutional review. *Gynecol Oncol* 2008; 108: 293-7 (**Level III**)

8) Murphy KT, Rotmensch J, Yamada SD, Mundt AJ. Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: Implications for adjuvant radiation therapy. *Int J Radiat Oncol Biol Phys* 2003; 55: 1272-6 (**Level III**)

#### **CQ45**

1) Hamilton CA, Cheung MK, Osann K, Chen L, Teng NN, Longacre TA, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. *Br J Cancer* 2006; 94: 642-6 (**Level III**)

2) Bristow RE, Duska LR, Montz FJ. The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma. *Gynecol Oncol* 2001; 81: 92-9 (**Level III**)

3) Memarzadeh S, Holschneider CH, Bristow RE, Jones NL, Fu YS, Karlan BY, et al. FIGO stage III and IV uterine papillary serous carcinoma: Impact of residual disease on survival. *Int J Gynecol Cancer* 2002; 12: 454-8 (**Level III**)

4) Moller KA, Gehrig PA, Van Le L, Secord AA, Schorge J. The role of optimal debulking in advanced stage serous carcinoma of the uterus. *Gynecol Oncol* 2004; 94: 170-4 (**Level III**)

- 5) Thomas MB, Mariani A, Cliby WA, Keeney GL, Podratz KC, Dowdy SC. Role of cytoreduction in stage III and IV uterine papillary serous carcinoma. *Gynecol Oncol* 2007; 107: 190-3 (**Level III**)
- 6) Thomas M, Mariani A, Wright JD, Madarek EO, Powell MA, Mutch DG, et al. Surgical management and adjuvant therapy for patients with uterine clear cell carcinoma: A multi-institutional review. *Gynecol Oncol* 2008; 108: 293-7 (**Level III**)
- 7) Randall ME, Filiaci VL, Muss H, Spiratos NM, Mannel RS, Fowler J, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: A Gynecologic Oncology Group study. *J Clin Oncol* 2006; 24: 36-44 (**Level II**)
- 8) Levenback C, Burke TW, Silva E, Morris M, Gershenson DM, Kavanagh JJ, et al. Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC). *Gynecol Oncol* 1992; 46: 317-21 (**Level III**)
- 9) Price FV, Chambers SK, Carcangiu ML, Kohorn EI, Schwartz PE, Chambers JT. Intravenous cisplatin, doxorubicin, and cyclophosphamide in the treatment of uterine papillary serous carcinoma (UPSC). *Gynecol Oncol* 1993; 51: 383-9 (**Level III**)
- 10) Hoskins PJ, Swenerton KD, Pike JA, Wong F, Lim P, Acquino-Parsons C, et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: A phase II study. *J Clin Oncol* 2001; 19: 4048-53 (**Level II**)
- 11) Ramondetta L, Burke TW, Levenback C, Bevers M, Bodurka-Bevers D, Gershenson DM. Treatment of uterine papillary serous carcinoma with paclitaxel. *Gynecol Oncol* 2001; 82: 156-61 (**Level III**)
- 12) Vaidya AP, Littell R, Krasner C, Duska LR. Treatment of uterine papillary serous carcinoma with platinum-based chemotherapy and paclitaxel. *Int J Gynecol Cancer* 2006; 16: 267-72 (**Level III**)

## Chapter 9 Carcinosarcoma and sarcoma

### CQ46

- 1) Akahira J, Tokunaga H, Toyoshima M, Takano T, Nagase S, Yoshinaga K, et al. Prognoses and prognostic factors of carcinosarcoma, endometrial stromal sarcoma and uterine leiomyosarcoma: A comparison with uterine endometrial adenocarcinoma. *Oncology* 2006; 71: 333-40 (**Level III**)
- 2) Kokawa K, Nishiyama K, Ikeuchi M, Ihara Y, Akamatsu N, Enomoto T, et al. Clinical outcomes of uterine sarcomas: Results from 14 years worth of experience in the Kinki district in Japan (1990-2003). *Int J Gynecol Cancer* 2006; 16: 1358-63 (**Level III**)
- 3) Sagae S, Yamashita K, Ishioka S, Nishioka Y, Terasawa K, Mori M, et al. Prooperative diagnosis and treatment results in 106 patients with uterine sarcoma in Hokkaido, Japan. *Oncology* 2004; 67: 33-9 (**Level III**)
- 4) Temkin SM, Hellmann M, Lee YC, Abulafia O. Early-stage carcinosarcoma of the uterus: The significance of lymph node count. *Int J Gynecol Cancer* 2007; 17: 215-9 (**Level III**)
- 5) Emoto M, Charnock-Jones DS, Licence DR, Ishiguro M, Kawai M, Yanaihara A, et al. Localization of the VEGF and angiopoietin genes in uterine carcinosarcoma. *Gynecol Oncol* 2004; 95: 474-82 (**Level III**)

### CQ47

- 1) Sutton GP, Blessing JA, Rosenshein N, Photopulos G, DiSaia PJ. Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study). *Am J Obstet Gynecol* 1989; 161: 309-12 (**Level III**)
- 2) Curtin JP, Blessing JA, Soper JT, DeGeest K. Paclitaxel in the treatment of carcinosarcoma of the uterus: A Gynecologic Oncology Group study. *Gynecol Oncol* 2001; 83: 268-70 (**Level III**)
- 3) Thigpen JT, Blessing JA, Orr JW Jr, DiSaia PJ. Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: A Gynecologic Oncology Group study. *Cancer Treat Rep* 1986; 70: 271-4 (**Level III**)
- 4) Homesley HD, Filiaci V, Markman M, Bitterman P, Eaton L, Kilgore LC, et al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: A Gynecologic Oncology Group study. *J Clin Oncol* 2007; 25: 526-31 (**Level II**)
- 5) Omura GA, Blessing JA, Major F, Lifshitz S, Ehrlich CE, Mangan C, et al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas : A Gynecologic Oncology Group study. *J Clin Oncol* 1985; 3: 1240-5 (**Level II**)

- 6) Peters WA 3rd, Rivkin SE, Smith MR, Tesh DE. Cisplatin and adriamycin combination chemotherapy for uterine stromal sarcomas and mixed mesodermal tumors. *Gynecol Oncol* 1989; 34 : 323-7 (**Level III**)
- 7) Sutton G, Kauderer J, Carson LF, Lentz SS, Whitney CW, Gallion H. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: A Gynecologic Oncology Group study. *Gynecol Oncol* 2005; 96; 630-4 (**Level III**)
- 8) Toyoshima M, Akahira J, Matsunaga G, Niikura H, Ito K, Yaegashi N, et al. Clinical experience with combination paclitaxel and carboplatin therapy for advanced or recurrent carcinosarcoma of the uterus. *Gynecol Oncol* 2004; 94: 774-8 (**Level III**)
- 9) Wolfson AH, Brady MF, Rocereto T, Mannel RS, Lee YC, Futoran RJ, et al. A Gynecologic Oncology Group randomized phase III trial of whole abdominal irradiation (WAI) vs cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. *Gynecol Oncol* 2007; 107: 177-85 (**Level II**)
- 10) Menczer J, Levy T, Piura B, Chetrit A, Altaras M, Meirovitz M, et al. A comparison between different postoperative treatment modalities of uterine carcinosarcoma. *Gynecol Oncol* 2005; 97; 166-70 (**Level III**)
- 11) Gerszten K, Faul C, Kounelis S, Huang Q, Kelley J, Jones MW. The impact of adjuvant radiotherapy on carcinosarcoma of the uterus. *Gynecol Oncol* 1998; 68: 8-13 (**Level III**)
- 12) Clayton Smith D, Kenneth Macdonald O, Gaffney DK. The impact of adjuvant radiation therapy on survival in women with uterine carcinosarcoma. *Radiother Oncol* 2008; 88: 227-32 (**Level III**)

#### **CQ48**

- 1) Homesley HD, Filiaci V, Markman M, Bitterman P, Eaton L, Kilgore LC, et al. Phase III trial of Ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: A Gynecologic Oncology Group study. *J Clin Oncol* 2007; 25: 526-31 (**Level II**)
- 2) Sutton G, Brunetto VL, Kilgore L, Soper JT, McGehee R, Olt G, et al. A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group study. *Gynecol Oncol* 2000; 79: 147-53 (**Level III**)
- 3) van Rijswijk RE, Vermorken JB, Reed N, Favalli G, Mendiola C, Zanaboni F, et al. Cisplatin, doxorubicin and ifosfamide in carcinosarcoma of the female genital tract. A phase II study of the European Organization for Research and Treatment of Cancer Gynaecological Cancer Group (EORTC 55923). *Eur J Cancer* 2003; 39: 481-7 (**Level III**)



- 4) Curtin JP, Blessing JA, Soper JT, DeGeest K. Paclitaxel in the treatment of carcinosarcoma of the uterus: A Gynecologic Oncology Group study. *Gynecol Oncol* 2001; 83: 268-70 (**Level III**)
- 5) Hoskins PJ, Le N, Ellard S, Lee U, Martin LA, Swenerton KD, et al. Carboplatin plus paclitaxel for advanced or recurrent uterine malignant mixed mullerian tumors. The British Columbia Cancer Agency experience. *Gynecol Oncol* 2008; 108: 58-62 (**Level III**)
- 6) Toyoshima M, Akahira J, Matsunaga G, Niikura H, Ito K, Yaegashi N, et al. Clinical experience with combination paclitaxel and carboplatin therapy for advanced or recurrent carcinosarcoma of the uterus. *Gynecol Oncol* 2004; 94: 774-8 (**Level III**)
- 7) Miller DS, Blessing JA, Schilder J, Munkarah A, Lee YC. Phase II evaluation of topotecan in carcinosarcoma of the uterus: A Gynecologic Oncology Group study. *Gynecol Oncol* 2005; 98: 217-21 (**Level III**)
- 8) Ansink AC, Cross PA, Scorer P, de Barros Lopes A, Monaghan JM. The hormonal receptor status of uterine carcinosarcomas (mixed müllerian tumours): An immunohistochemical study. *J Clin Pathol* 1997; 50: 328-31 (**Level IV**)
- 9) Yoshinaga M, Togami S, Tsuji T, Fukamachi N, Kamio M, Yanagi M, et al. Clinical outcome of metastatic uterine leiomyosarcoma and carcinosarcoma in a single institute. *J Obstet Gynecol Res* 2007; 33: 818-22 (**Level IV**)

#### **CQ49**

- 1) Sagae S, Yamashita K, Ishioka S, Nishioka Y, Terasawa K, Mori M, et al. Preoperative diagnosis and treatment results in 106 patients with uterine sarcoma in Hokkaido, Japan. *Oncology* 2004; 67: 33-9 (**Level III**)
- 2) Wain GV, Hacker NF. Genital sarcomas: Clinical Features and Treatment. In: Burghart E, Webb MJ, Monaghan JM, Kindermann G eds, *Surgical Gynecologic Oncology* 14th ed. New York: Georg Thieme Verlag, 1993; 408-16 (**Level IV**)
- 3) Goff BA, Rice LW, Fleischhacker D, Muntz HG, Falkenberry SS, Nikrui N, et al. Uterine leiomyosarcoma and endometrial stromal sarcoma: Lymph node metastases and sites of recurrence. *Gynecol Oncol* 1993; 50: 105-9 (**Level III**)
- 4) Kapp DS, Shin JY, Chan JK. Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: Emphasis on impact of lymphadenectomy and oophorectomy. *Cancer* 2008; 112: 820-30 (**Level III**)
- 5) Dinh TA, Oliva EA, Fuller AF, Lee H, Goodman A. The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990-1999) at the Massachusetts General Hospital. *Gynecol Oncol* 2004; 92: 648-52 (**Level III**)

- 6) Giuntoli RL 2nd, Metzinger DS, DiMarco CS, Cha SS, Sloan JA, Keeney GL, et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus; Prognostic indicators, surgical management, and adjuvant therapy. *Gynecol Oncol* 2003; 89: 460-9
- 7) The National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Uterine Neoplasms, V.1 2008. Available at: [http://www.nccn.org/professionals/physician\\_gls/PDF/uterine.pdf](http://www.nccn.org/professionals/physician_gls/PDF/uterine.pdf)
- 8) Omura GA, Blessing JA, Major F, Lifshitz S, Ehrlich CE, Mangan C, et al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: A Gynecologic Oncology Group study. *J Clin Oncol* 1985; 3: 1240-5 (**Level II**)
- 9) Piver MS, Lele SB, Marchetti DL, Emrich LJ. Effect of adjuvant chemotherapy on time to recurrence and survival of stage I uterine sarcoma. *J Surg Oncol* 1988; 38: 233-9 (**Level III**)
- 10) Thigpen JT, Blessing JA, Beecham J, Homesley H, Yordan E. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: A Gynecologic Oncology Group study. *J Clin Oncol* 1991; 9: 1962-6 (**Level III**)
- 11) Hensley ML, Blessing JA, Mannel R, Rose PG. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II trial. *Gynecol Oncol* 2008; 109: 329-34 (**Level III**)
- 12) Hornback NB, Omura G, Major FJ. Observations on the use of adjuvant radiation therapy in patients with stage I and II uterine sarcoma. *Int J Radiat Oncol Biol Phys* 1986; 12: 2127-30 (**Level III**)
- 13) Reed NS, Mangioni C, Malmström H, Scarfone G, Poveda A, Pecorelli S, et al. Phase III randomized study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: An European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group study (protocol 55874). *Eur J Cancer* 2008; 44: 808-18 (**Level II**)
- 14) Dusenbery KE, Potish RA, Judson P. Limitations of adjuvant radiotherapy for uterine sarcomas spread beyond the uterus. *Gynecol Oncol* 2004; 94: 191-6 (**Level III**)
- 15) Bodner K, Bodner-Adler B, Kimberger O, Czerwenka K, Leodolter S, Mayerhofer K. Estrogen and progesterone receptor expression in patients with uterine leiomyosarcoma and correlation with different clinicopathological parameters. *Anticancer Res* 2003; 23: 729-32 (**Level III**)

## CQ50

- 1) Sagae S, Yamashita K, Ishioka S, Nishioka Y, Terasawa K, Mori M, et al. Preoperative diagnosis and treatment results in 106 patients with uterine sarcoma in Hokkaido, Japan. *Oncology* 2004; 67: 33-9 (**Level III**)
- 2) Hendrickson MR, Tavassoli FA, Kempson RL, McCluggage WG, Haller U, Kubik-Huch RA. Mesenchymal tumours and related lesions. In: Tavassoli FA, Devilee P, eds. *World Health Organization Classification of Tumours. Pathology & Genetics. Tumours of the Breast and Female Genital Organs*. Lyon: IARC Press, 2003; 233-44 (規約)
- 3) Gadducci A, Sartori E, Landoni F, Zola P, Maggino T, Urgesi A, et al. Endometrial stromal sarcoma: Analysis of treatment failures and survival. *Gynecol Oncol* 1996; 63: 247-53 (**Level IV**)
- 4) The National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Uterine neoplasms, V.1. 2008. Available at: [http://www.nccn.org/professionals/physician\\_gls/PDF/uterine.pdf](http://www.nccn.org/professionals/physician_gls/PDF/uterine.pdf) (**Guideline**)
- 5) Amant F, De Knijf A, Van Calster B, Leunen K, Neven P, Berteloot P, et al. Clinical study investigating the role of lymphadenectomy, surgical castration and adjuvant hormonal treatment in endometrial stromal sarcoma. *Br J Cancer* 2007; 97: 1194-9 (**Level III**)
- 6) Li AJ, Giuntoli RL 2nd, Drake R, Byun SY, Rojas F, Barbuto D, et al. Ovarian preservation in stage I low-grade endometrial stromal sarcomas. *Obstet Gynecol* 2005; 106: 1304-8 (**Level III**)
- 7) Leath CA 3rd, Huh WK, Hyde J Jr, Cohn DE, Resnick KE, Taylor NP, et al. A multi-institutional review of outcomes of endometrial stromal sarcoma. *Gynecol Oncol* 2007; 105: 630-4 (**Level III**)
- 8) Goff BA, Rice LW, Fleischhacker D, Muntz HG, Falkenberry SS, Nikrui N, et al. Uterine leiomyosarcoma and endometrial stromal sarcoma: Lymph node metastases and sites of recurrence. *Gynecol Oncol* 1993; 50: 105-9 (**Level III**)
- 9) Riopel J, Plante M, Renaud MC, Roy M, Têtu B. Lymph node metastases in low-grade endometrial stromal sarcoma. *Gynecol Oncol* 2005; 96: 402-6 (**Level III**)
- 10) Mansi JL, Ramachandra S, Wiltshaw E, Fisher C. Endometrial stromal sarcomas. *Gynecol Oncol* 1990; 36: 113-8 (**Level IV**)
- 11) Garrett A, Quinn MA. Hormonal therapies and gynaecological cancers, *Best Pract Res Clin Obstet Gynaecol* 2008; 22: 407-21 (**Level IV**)

- 12) Tabata T, Takeshima N, Hirai Y, Hasumi K. Low-grade endometrial stromal sarcoma with cardiovascular involvement—a report of three cases. *Gynecol Oncol* 1999; 75: 495-8 (**Level IV**)
- 13) Wade K, Quinn MA, Hammond I, Williams K, Cauchi M. Uterine sarcoma: Steroid receptors and response to hormonal therapy. *Gynecol Oncol* 1990; 39: 364-7 (**Level IV**)
- 14) Weitmann HD, Knocke TH, Kucera H, Pötter R. Radiation therapy in the treatment of endometrial stromal sarcoma. *Int J Radiat Oncol Bio Phys* 2001; 49: 739-48 (**Level III**)
- 15) Reed NS, Mangioni C, Malmström H, Scarfone G, Poveda A, Pecorelli S, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: An European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group study (protocol 55874). *Eur J Cancer* 2008; 44: 808-18 (**Level II**)

#### **CQ51**

- 1) Giuntoli RL 2nd, Garrett-Mayer E, Bristow RE, Gostout BS. Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma. *Gynecol Oncol* 2007; 106: 82-8 (**Level III**)
- 2) Omura GA, Major FJ, Blessing JA, Sedlacek TV, Thigpen JT, Creasman WT, et al. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. *Cancer* 1983; 52: 626-32 (**Level II**)
- 3) Sutton GP, Blessing JA, Barret RJ, McGehee R. Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: A Gynecologic Oncology Group study. *Am J Obstet Gynecol* 1992; 166: 556-9 (**Level III**)
- 4) Thigpen JT, Blessing JA, Beecham J, Homesley H, Yordan E. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: A Gynecologic Oncology Group study. *J Clin Oncol* 1991; 9: 1962-6 (**Level III**)
- 5) Thigpen JT, Blessing JA, Wilbanks GD. Cisplatin as second-line chemotherapy in the treatment of advanced or recurrent leiomyosarcoma of the uterus. A phase II trial of the Gynecologic Oncology Group. *Am J Clin Oncol* 1986; 9: 18-20 (**Level III**)
- 6) Slayton RE, Blessing JA, Angel C, Berman M. Phase II trial of etoposide in the management of advanced and recurrent leiomyosarcoma of the uterus: A Gynecologic Oncology Group study. *Cancer Treat Rep* 1987; 71: 1303-4 (**Level III**)

- 7) Rose PG, Blessing JA, Soper JT, Barter JF. Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: A Gynecologic Oncology Group study. *Gynecol Oncol* 1998; 70: 267-71 (**Level III**)
- 8) Sutton G, Blessing JA, Ball H. Phase II trial of paclitaxel in leiomyosarcoma of the uterus: A Gynecologic Oncology Group study. *Gynecol Oncol* 1999; 74: 346-9 (**Level III**)
- 9) Sutton G, Blessing JA, Park R, DiSaia PJ, Rosenshein N. Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcoma previously unexposed to chemotherapy: A study of the Gynecologic Oncology Group. *Obstet Gynecol* 1996; 87: 747-50 (**Level III**)
- 10) Muss HB, Bundy B, DiSaia PJ, Homesley HD, Fowler WC Jr, Creasman W, et al. Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group). *Cancer* 1985; 55: 1648-53 (**Level II**)
- 11) Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: Results of a phase II trial. *J Clin Oncol* 2002; 20: 2824-31 (**Level III**)
- 12) Hensley ML, Blessing JA, Mannel R, Rose PG. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II trial. *Gynecol Oncol* 2008; 109: 329-34 (**Level III**)
- 13) Hensley ML, Blessing JA, DeGeest K, Abulafia O, Rose PG, Homesley HD. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II study. *Gynecol Oncol* 2008; 109: 323-8 (**Level III**)
- 14) Berchuck A, Rubin SC, Hoskins WJ, Saigo PE, Pierce VK, Lewis JL Jr. Treatment of uterine leiomyosarcoma. *Obstet Gynecol* 1988; 71: 845-50 (**Level IV**)
- 15) The National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Uterine neoplasms, V.1. 2008. Available at: [http://www.nccn.org/professionals/physician\\_gls/PDF/uterine.pdf](http://www.nccn.org/professionals/physician_gls/PDF/uterine.pdf) (**Guideline**)
- 16) Bodner K, Bodner-Adler B, Kimberger O, Czerwenka K, Leodolter S, Mayerhofer K. Estrogen and progesterone receptor expression in patients with uterine leiomyosarcoma and correlation with different clinicopathological parameters. *Anticancer Res* 2003; 23: 729-32 (**Level IV**)
- 17) Pink D, Lindner T, Mrozek A, Kretzschmar A, Thuss-Patience PC, Dörken B, et al. Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal

sarcoma: Single center experience with 10 cases and review of the literature. *Gynecol Oncol* 2006; 101: 464-9 (**Level IV**)

18) Krauss K, Bachmann C, Hartmann JT, Siegmann K, Sotlar K, Wallwiener D, et al. Management of late recurrence of a low-grade endometrial stromal sarcoma (LGESS): Treatment with letrozole. *Anticancer Res* 2007; 27: 3477-80 (**Level IV**)

19) Wade K, Quinn MA, Hammond I, Williams K, Cauchi M. Uterine sarcoma: Steroid receptors and response to hormonal therapy. *Gynecol Oncol* 1990; 39: 364-7 (**Level IV**)

20) Mansi JL, Ramachandra S, Wiltshaw E, Fisher C. Endometrial stromal sarcomas. *Gynecol Oncol* 1990; 36: 113-8 (**Level IV**)

21) Berchuck A, Rubin SC, Hoskins WJ, Saigo PE, Pierce VK, Lewis JL Jr. Treatment of endometrial stromal tumors. *Gynecol Oncol* 1990; 36: 60-5 (**Level IV**)

22) Peters WA 3rd, Rivkin SE, Smith MR, Tesh DE. Cisplatin and adriamycin combination chemotherapy for uterine stromal sarcoma and mixed mesodermal tumors. *Gynecol Oncol* 1989; 34: 323-7 (**Level III**)

23) Yamawaki T, Shimizu Y, Hasumi K. Treatment of stage IV "high grade" endometrial stromal sarcoma with ifosfamide, adriamycin, and cisplatin. *Gynecol Oncol* 1997; 64: 265-9 (**Level IV**)

24) Weitmann HD, Knocke TH, Kucera H, Pötter R. Radiation therapy in the treatment of endometrial stromal sarcoma. *Int J Radiat Oncol Bio Phys* 2001; 49: 739-48 (**Level III**)